Walgreens Boots Alliance (WBA) 10-Q 4 Jan 24 2024 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Nov. 30, 2023	Dec. 29, 2023
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Nov. 30, 2023
Document Transition Report	false
Entity File Number	001-36759
Entity Registrant Name	WALGREENS BOOTS ALLIANCE, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	47-1758322
Entity Address, Address Line One	108 Wilmot Road
Entity Address, City or Town	Deerfield
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60015
City Area Code	847
Local Phone Number	315-3700
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		862,375,527
Entity Central Index Key	0001618921
Current Fiscal Year End Date	--08-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1
Amendment Flag	false
Common Stock, $0.01 par value
Document Information [Line Items]
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	WBA
Security Exchange Name	NASDAQ
3.600% Walgreens Boots Alliance, Inc. notes due 2025
Document Information [Line Items]
Title of 12(b) Security	3.600% Walgreens Boots Alliance, Inc. notes due 2025
Trading Symbol	WBA25
Security Exchange Name	NASDAQ
2.125% Walgreens Boots Alliance, Inc notes due 2026
Document Information [Line Items]
Title of 12(b) Security	2.125% Walgreens Boots Alliance, Inc. notes due 2026
Trading Symbol	WBA26
Security Exchange Name	NASDAQ

CONSOLIDATED CONDENSED BALANCE

CONSOLIDATED CONDENSED BALANCE SHEETS - USD ($) $ in Millions	Nov. 30, 2023	Aug. 31, 2023
Current assets:
Cash and cash equivalents	$ 784	$ 739
Accounts receivable, net	5,972	5,381
Inventories	9,454	8,257
Other current assets	1,134	1,127
Total current assets	17,345	15,503
Non-current assets:
Property, plant and equipment, net	11,176	11,587
Operating lease right-of-use assets	21,708	21,667
Goodwill	28,184	28,187
Intangible assets, net	13,278	13,635
Equity method investments (see Note 5)	3,400	3,497
Other non-current assets	2,732	2,550
Total non-current assets	80,478	81,125
Total assets	97,823	96,628
Current liabilities:
Short-term debt	1,670	917
Trade accounts payable (see Note 16)	13,593	12,635
Operating lease obligations	2,350	2,347
Accrued expenses and other liabilities	8,226	8,426
Income taxes	276	209
Total current liabilities	26,116	24,535
Non-current liabilities:
Long-term debt	7,585	8,145
Operating lease obligations	22,132	22,124
Deferred income taxes	1,279	1,318
Accrued litigation obligations	6,366	6,261
Other non-current liabilities	6,589	5,757
Total non-current liabilities	43,951	43,605
Commitments and contingencies (see Note 10)
Total liabilities	70,066	68,140
Redeemable non-controlling interests	169	167
Equity:
Preferred stock $.01 par value; authorized 32 million shares, none issued	0	0
Common stock $.01 par value; authorized 3.2 billion shares; issued 1,172,513,618 at November 30, 2023 and August 31, 2023	12	12
Paid-in capital	10,617	10,661
Retained earnings	32,573	33,058
Accumulated other comprehensive loss	(2,995)	(2,993)
Treasury stock, at cost; 310,346,648 shares at November 30, 2023 and 308,839,832 shares at August 31, 2023	(20,725)	(20,717)
Total Walgreens Boots Alliance, Inc. shareholders’ equity	19,481	20,020
Non-controlling interests	8,107	8,302
Total equity	27,588	28,322
Total liabilities, redeemable non-controlling interests and equity	$ 97,823	$ 96,628

CONSOLIDATED CONDENSED BALANC_2

CONSOLIDATED CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares	Nov. 30, 2023	Aug. 31, 2023
Equity:
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, authorized (in shares)	32,000,000	32,000,000
Preferred stock, issued (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized shares (in shares)	3,200,000,000	3,200,000,000
Common stock, issued (in shares)	1,172,513,618	1,172,513,618
Treasury stock, at cost (in shares)	310,346,648	308,839,832

CONSOLIDATED CONDENSED STATEMEN

CONSOLIDATED CONDENSED STATEMENTS OF EQUITY - USD ($) $ in Millions	Total	Common stock	Treasury Stock, Common	Paid-in capital	Accumulated other comprehensive income (loss)	Retained earnings	Noncontrolling interests
Beginning balance (in shares) at Aug. 31, 2022		864,639,457
Beginning balance at Aug. 31, 2022	$ 29,366	$ 12	$ (20,683)	$ 10,950	$ (2,805)	$ 37,801	$ 4,091
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(3,793)					(3,721)	(72)
Other comprehensive loss, net of tax	(10)				(11)		0
Dividends declared and distributions	(459)					(415)	(44)
Treasury stock purchases (in shares)		(4,438,228)
Treasury stock purchases	(150)		(150)
Employee stock purchase and option plans (in shares)		2,141,006
Employee stock purchase and option plans	6		71	(64)
Stock-based compensation	55			24			31
Other	(433)			(433)
Ending balance (in shares) at Nov. 30, 2022		862,342,235
Ending balance at Nov. 30, 2022	24,582	$ 12	(20,762)	10,477	(2,815)	33,664	4,006
Beginning balance (in shares) at Aug. 31, 2023		863,673,786
Beginning balance at Aug. 31, 2023	28,322	$ 12	(20,717)	10,661	(2,993)	33,058	8,302
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(278)					(67)	(211)
Other comprehensive loss, net of tax	(5)				(2)		(3)
Dividends declared and distributions	(418)					(418)	0
Treasury stock purchases (in shares)		(3,100,000)
Treasury stock purchases	(69)		(69)
Employee stock purchase and option plans (in shares)		1,593,184
Employee stock purchase and option plans	(2)		61	(64)
Stock-based compensation	44			15			30
Other	(6)			5			10
Ending balance (in shares) at Nov. 30, 2023		862,166,970
Ending balance at Nov. 30, 2023	$ 27,588	$ 12	$ (20,725)	$ 10,617	$ (2,995)	$ 32,573	$ 8,107

CONSOLIDATED CONDENSED STATEM_2

CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Nov. 30, 2023	Nov. 30, 2022
Income Statement [Abstract]
Sales	$ 36,707	$ 33,382
Cost of sales	29,937	26,429
Gross profit	6,771	6,953
Selling, general and administrative expenses	6,851	13,158
Equity earnings in Cencora	42	53
Operating loss	(39)	(6,151)
Other (expense) income, net	(220)	992
Loss before interest and income tax benefit	(259)	(5,159)
Interest expense, net	99	110
Loss before income tax benefit	(358)	(5,270)
Income tax benefit	(74)	(1,447)
Post-tax earnings from other equity method investments	6	7
Net loss	(278)	(3,816)
Net loss attributable to non-controlling interests	(210)	(94)
Net loss attributable to Walgreens Boots Alliance, Inc.	$ (67)	$ (3,721)
Earnings Per Share, Basic [Abstract]
Total (in dollars per share)	$ (0.08)	$ (4.31)
Earnings Per Share, Diluted [Abstract]
Total (in dollars per share)	$ (0.08)	$ (4.31)
Weighted average common shares outstanding:
Basic (in shares)	863	863.6
Diluted (in shares)	863	863.6

CONSOLIDATED CONDENSED STATEM_3

CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Millions	3 Months Ended
	Nov. 30, 2023	Nov. 30, 2022
Statement of Comprehensive Income [Abstract]
Net loss	$ (278)	$ (3,816)
Other comprehensive loss, net of tax:
Pension/post-retirement obligations	56	(5)
Unrealized gain (loss) on cash flow hedges and other	5	(2)
Net investment hedges gain (loss)	3	(29)
Share of other comprehensive (loss) income of equity method investments	(15)	4
Cumulative translation adjustments	(54)	23
Total other comprehensive loss	(5)	(10)
Total comprehensive loss	(283)	(3,826)
Comprehensive loss attributable to non-controlling interests	(214)	(94)
Comprehensive loss attributable to Walgreens Boots Alliance, Inc.	$ (70)	$ (3,732)

CONSOLIDATED CONDENSED STATEM_4

CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	3 Months Ended
	Nov. 30, 2023	Nov. 30, 2022
Cash flows from operating activities:
Net loss	$ (278)	$ (3,816)
Adjustments to reconcile net loss to net cash (used for) provided by operating activities:
Depreciation and amortization	616	495
Deferred income taxes	(196)	(1,602)
Stock compensation expense	51	222
Earnings from equity method investments	(48)	(61)
Impairment of intangibles and long-lived assets	165	94
Gain on sale of equity method investments	(139)	(969)
Gain on sale-leaseback transactions	(160)	(189)
Loss on variable prepaid forward contracts	366	0
Other	35	(34)
Changes in certain assets and liabilities:
Accounts receivable, net	(618)	151
Inventories	(1,180)	(918)
Other current assets	(42)	(68)
Trade accounts payable	966	867
Accrued expenses and other liabilities	205	(269)
Income taxes	96	153
Accrued litigation obligations	(54)	6,494
Other non-current assets and liabilities	(67)	(58)
Net cash (used for) provided by operating activities	(281)	493
Cash flows from investing activities:
Additions to property, plant and equipment	(506)	(610)
Proceeds from sale-leaseback transactions	427	409
Proceeds from sale of other assets	304	2,068
Business, investment and asset acquisitions, net of cash acquired	(109)	(80)
Other	(31)	70
Net cash provided by investing activities	85	1,858
Cash flows from financing activities:
Net change in short-term debt with maturities of 3 months or less	155	22
Proceeds from debt	3,826	17
Payments of debt	(3,776)	(11)
Proceeds from variable prepaid forward contracts	424	0
Treasury stock purchases	(69)	(150)
Cash dividends paid	(415)	(415)
Other	41	(63)
Net cash provided by (used for) financing activities	186	(599)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	0	4
Changes in cash, cash equivalents and restricted cash:
Net (decrease) increase in cash, cash equivalents and restricted cash	(10)	1,756
Cash, cash equivalents and restricted cash at beginning of period	856	2,558
Cash, cash equivalents and restricted cash at end of period	$ 846	$ 4,314

Accounting policies

Accounting policies	3 Months Ended
	Nov. 30, 2023
Accounting Policies [Abstract]
Accounting policies	Accounting policies Basis of presentation The Consolidated Condensed Financial Statements of Walgreens Boots Alliance, Inc. and its subsidiaries (“Walgreens Boots Alliance” or the “Company”) included herein have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. The Consolidated Condensed Financial Statements include all subsidiaries in which the Company holds a controlling interest and certain variable interest entities (“VIEs”) for which the Company is the primary beneficiary. The Company uses the equity method of accounting for equity investments in less than majority-owned companies if the investment provides the ability to exercise significant influence. All intercompany transactions have been eliminated. The Consolidated Condensed Financial Statements included herein are unaudited. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited Consolidated Condensed Financial Statements should be read in conjunction with the audited financial statements and the notes thereto included in the Walgreens Boots Alliance Annual Report on Form 10-K for the fiscal year ended August 31, 2023, as amended by Form 10-K/A for the fiscal year ended August 31, 2023 filed on November 22, 2023. The preparation of financial statements in accordance with GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. The Company bases its estimates on the information available at the time, its experiences and various other assumptions believed to be reasonable under the circumstances. Adjustments may be made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. Actual results may differ. In the opinion of management, the unaudited Consolidated Condensed Financial Statements for the interim periods presented include all adjustments necessary to present a fair statement of the results for such interim periods. Adverse global macroeconomic conditions, the impact of opioid-related claims and litigation settlements, the influence of certain holidays, seasonality, foreign currency rates, changes in vendor, payor and customer relationships and terms, strategic transactions including acquisitions and dispositions, asset impairments, changes in laws and regulations in the markets in which the Company operates and other factors on the Company’s operations and net earnings for any period may not be comparable to the same period in previous years. Certain amounts in the Consolidated Condensed Financial Statements and accompanying notes may not add due to rounding. Percentages have been calculated using unrounded amounts for all periods presented. Certain prior period data, has been reclassified in the Consolidated Condensed Financial Statements and accompanying notes to conform to the current period presentation. Adoption of new accounting pronouncements Acquired contract assets and contract liabilities in a business combination In October 2021, the FASB issued Accounting Standards Update (“ASU”) 2021-08, Business Combinations (Topic 805) - Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU requires an entity to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606 (Revenue from Contracts with Customers). This ASU is expected to reduce diversity in practice and increase comparability for both the recognition and measurement of acquired revenue contracts with customers at the date of and after a business combination. This ASU is effective for business combinations completed in fiscal years beginning after December 15, 2022 (fiscal 2024). The Company adopted this ASU effective September 1, 2023 and the adoption did not impact the Company's results of operations, cash flows, or financial position. Liabilities — Supplier Finance Programs In September 2022, the FASB issued ASU 2022-04, Liabilities—Supplier Finance Programs (Topic 405-50) - Disclosure of Supplier Finance Program Obligations. This ASU requires that a buyer in a supplier finance program disclose sufficient information about the program to allow a user of financial statements to understand the program’s nature, activity during the period, changes from period to period, and potential magnitude. This ASU is expected to improve financial reporting by requiring new disclosures about the programs, thereby allowing financial statement users to better consider the effect of the programs on an entity’s working capital, liquidity, and cash flows. This ASU is effective for fiscal years beginning after December 15, 2022 (fiscal 2024), except for the amendment on roll forward information which is effective for fiscal years beginning after December 15, 2023 (fiscal 2025). The Company adopted this ASU effective September 1, 2023 and the adoption did not impact the Company's disclosures within these Consolidated Condensed Financial Statements. New accounting pronouncements not yet adopted Leases — Common Control Arrangements In March 2023, the FASB issued ASU 2023-01, Leases (Topic 842) – Common Control Arrangements. The ASU amends the accounting for leasehold improvements in common control arrangements by requiring a lessee in a common control lease arrangement to amortize leasehold improvements that it owns over the improvements’ useful life to the common control group, regardless of the lease term, if the lessee continues to control the use of the underlying asset through a lease. Further, a lessee that no longer controls the use of the underlying asset will derecognize the remaining carrying amount of the improvements through an adjustment to equity, reflecting the transfer of the asset to the lessor under common control. This ASU is effective for fiscal years beginning after December 15, 2023 (fiscal 2025), including interim periods within those fiscal years. Early adoption is permitted in any annual or interim period as of the beginning of the related fiscal year. The Company is evaluating the effect of adopting this new accounting guidance. Segment Reporting - Improvements to Reportable Segment Disclosures In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures. This ASU is expected to improve disclosures related to an entity’s reportable segments and provide additional, more detailed information about a reportable segment’s expenses. This ASU is effective for fiscal years beginning after December 15, 2023 (fiscal 2025) and interim periods within fiscal years beginning after December 15, 2024 (fiscal 2026). The amendments in this ASU must be applied on a retrospective basis to all prior periods presented in the financial statements and early adoption is permitted. The Company is currently evaluating the effect of adopting this new accounting guidance. Improvements to Income Tax Disclosures

Acquisitions and other Investme

Acquisitions and other Investments	3 Months Ended
	Nov. 30, 2023
Business Combination and Asset Acquisition [Abstract]
Acquisitions and other Investments	Acquisitions and other investments Summit acquisition On January 3, 2023, Village Practice Management Company, LLC (“VillageMD”), through its parent company, following an internal reorganization, completed the acquisition of WP CityMD TopCo (“Summit”), a provider of primary, specialty and urgent care in exchange, for $7.0 billion aggregate consideration, consisting of $4.85 billion of cash consideration paid, $2.05 billion in preferred units of VillageMD issued to Summit equity holders and $100 million of cash to be paid one year following closing. The cash consideration includes $87 million of cash paid to fund acquisition-related bonuses to Summit employees which was recognized as a compensation expense of the Company. In addition, VillageMD paid off approximately $1.9 billion in net debt of Summit. In connection with the amended Agreement and Plan of Merger, and in order to finance the acquisition, the Company and Cigna Health & Life Insurance Company acquired preferred units of VillageMD in exchange for $1.75 billion and $2.5 billion in aggregate consideration, respectively. Following the Summit acquisition, the Company remains the largest and consolidating equity holder of VillageMD with ownership of approximately 53% of the outstanding equity interests on a fully diluted basis. Further, the Company entered into a credit agreement with VillageMD pursuant to which the Company provided VillageMD senior secured credit facilities in the aggregate amount of $2.25 billion, consisting of (i) a senior secured term loan facility in an aggregate original principal amount of $1.75 billion to support the acquisition of Summit; and (ii) a senior secured revolving credit facility in an aggregate original committed amount of $500 million available for general corporate purposes. In connection with the issuance of the senior secured credit facilities, the Company received a $220 million credit for certain fees payable by VillageMD in the form of preferred units of VillageMD. The intercompany facilities eliminate in consolidation. The Company accounted for this acquisition as a business combination resulting in consolidation of Summit within the U.S. Healthcare segment in its financial statements. As of November 30, 2023, the Company had not completed the analysis to assign fair values to all tangible and intangible assets acquired and liabilities assumed. As such, the preliminary purchase price allocation will be subject to further refinement and may change. These changes may relate to the allocation of purchase consideration to all tangible and intangible assets acquired and identified and liabilities assumed. In the three months ended November 30, 2023, the Company recorded certain measurement period adjustments, resulting in an increase to goodwill of $24 million. The following table summarizes the consideration for the acquisition and the amounts of identified assets acquired and liabilities assumed at the date of the transaction (in millions): Purchase price allocation Cash consideration 1 $ 4,778 Deferred consideration 100 Summit debt paid at closing 1,963 Fair value of equity consideration 2 1,971 Fair value of non-controlling interests 13 Total $ 8,825 Identifiable assets acquired and liabilities assumed: Cash and cash equivalents $ 69 Accounts receivable, net 382 Property, plant and equipment 607 Intangible assets 3 3,359 Operating lease right-of-use assets 756 Other assets 173 Operating lease obligations (773) Deferred tax liability (737) Other liabilities (470) Total identifiable net assets $ 3,366 Goodwill $ 5,460 1. Cash consideration excludes $87 million of cash paid to fund acquisition-related bonuses to Summit employees which was recognized as compensation expense of the Company. 2. The fair value of the non-controlling interests was calculated based on the implied equity value of VillageMD, allocated to all units on an as-converted basis. 3. Intangibles acquired include provider networks and trade names with fair values of $1.9 billion and $1.5 billion, respectively. Estimated useful lives are 15 years and 11 to 15 years, respectively. The goodwill represents anticipated future growth and expansion opportunities into new healthcare offerings and new markets. $433 million of the goodwill is expected to be tax deductible. Supplemental pro forma information - Summit The following table represents unaudited supplemental pro forma consolidated sales for the three months ended November 30, 2022, as if the acquisition of Summit had occurred at the beginning of fiscal 2022. The unaudited pro forma information has been prepared for comparative purposes only and is not intended to be indicative of what the Company's results would have been had the acquisition occurred at the beginning of fiscal 2022 or results which may occur in the future. Three months ended November 30, (Unaudited, in millions) 2022 Sales $ 34,099 No Summit sales were included in the Consolidated Condensed Statements of Earnings for the three months ended November 30, 2022. Pro forma net earnings of the Company, assuming the Summit acquisition had occurred at the beginning of fiscal 2022, would not be materially different from the results reported. Other acquisitions On March 3, 2023, the Company completed the acquisition of Starling MSO Holdings, LLC (“Starling”), a primary care and multi-specialty group, for total consideration of $284 million. Total consideration includes $222 million of cash consideration and $62 million of VillageMD equity issued to Starling equity holders, including employees. VillageMD equity issued to employees will be recognized as compensation expense in the future. As a result of the acquisition, the Company recognized goodwill and intangible assets of $100 million and $128 million, respectively. As of November 30, 2023, the Company had not completed the analysis to assign fair values to all tangible and intangible assets acquired and liabilities assumed. As such, the preliminary purchase price allocation will be subject to further refinement and may change. The Company acquired certain prescription files and related pharmacy inventory primarily in the United States (“U.S.”) for the aggregate purchase price of $103 million and $55 million during the three months ended November 30, 2023 and 2022, respectively.

Exit and disposal activities

Exit and disposal activities	3 Months Ended
	Nov. 30, 2023
Restructuring and Related Activities [Abstract]
Exit and disposal activities	Exit and disposal activities Transformational Cost Management Program On December 20, 2018, the Company announced a transformational cost management program that was expected to deliver in excess of $2.0 billion of annual cost savings by fiscal 2022 (the “Transformational Cost Management Program”). The Company achieved this goal at the end of fiscal 2021. On October 12, 2021, the Company expanded and extended the Transformational Cost Management Program through the end of fiscal 2024 and increased its annual cost savings target to $3.3 billion by the end of fiscal 2024. In fiscal 2022, the Company increased its annual cost savings target from $3.3 billion to $3.5 billion, by the end of fiscal 2024. In fiscal 2023, the Company increased its annual cost savings target from $3.5 billion to $4.5 billion, by the end of fiscal 2024. The Company is currently on track to achieve the savings target. The Transformational Cost Management Program, which is multi-faceted and includes divisional optimization initiatives, global smart spending, global smart organization and the transformation of the Company’s information technology (“IT”) capabilities, is designed to help the Company achieve increased cost efficiencies. To date, the Company has taken actions across all aspects of the Transformational Cost Management Program which focus primarily on the U.S. Retail Pharmacy and International reportable segments along with the Company's global functions. Divisional optimization within the Company’s segments includes activities such as optimization of stores. Through the Transformational Cost Management Program the Company plans to reduce its presence by up to 650 Boots stores in the UK and approximately 650 to 700 stores in the U.S. As of November 30, 2023, the Company has closed 364 and 563 stores in the UK and U.S., respectively. The Company estimates cumulative pre-tax charges to its GAAP financial results for the Transformational Cost Management Program to be $4.1 billion to $4.4 billion, of which pre-tax charges for exit and disposal activities are estimated to be $3.8 billion to $4.1 billion. In addition to the impacts discussed above, as a result of the actions related to store closures taken under the Transformational Cost Management Program, the Company recorded $508 million of transition adjustments to decrease retained earnings due to the adoption of the new lease accounting standard (Topic 842) that became effective on September 1, 2019. From the inception of the Transformational Cost Management Program to November 30, 2023, the Company has recognized cumulative pre-tax charges to its financial results in accordance with GAAP of $3.2 billion, which were primarily recorded in Selling, general and administrative expenses within the Consolidated Condensed Statements of Earnings. These charges included $1.2 billion related to lease obligations and other real estate costs, $894 million in asset impairments, $900 million in employee severance and business transition costs and $257 million of IT transformation and other exit costs. Costs related to exit and disposal activities under the Transformational Cost Management Program for the three months ended November 30, 2023 and 2022, respectively, were as follows (in millions): Three months ended November 30, 2023 U.S. Retail Pharmacy International U.S. Healthcare Corporate and Other Walgreens Boots Alliance, Inc. Lease obligations and other real estate costs $ 36 $ — $ — $ — $ 36 Asset impairments 3 7 — — 10 Employee severance and business transition costs 22 (1) 2 4 27 Information technology transformation and other exit costs 3 — — — 4 Total pre-tax exit and disposal charges $ 64 $ 6 $ 2 $ 4 $ 77 Three months ended November 30, 2022 U.S. Retail Pharmacy International U.S. Healthcare Corporate and Other Walgreens Boots Alliance, Inc. Lease obligations and other real estate costs $ 79 $ — $ — $ — $ 79 Asset impairments 18 — — — 18 Employee severance and business transition costs 11 1 — 4 16 Information technology transformation and other exit costs 11 5 — — 17 Total pre-tax exit and disposal charges $ 119 $ 6 $ — $ 4 $ 130 The changes in liabilities and assets related to the exit and disposal activities under Transformational Cost Management Program include the following (in millions): Lease obligations and other real estate costs Asset impairments Employee severance and business transition costs Information technology transformation and other exit costs Total Balance at August 31, 2023 $ 10 $ — $ 70 $ 22 $ 102 Costs 36 10 27 4 77 Payments (21) — (35) (14) (70) Other (10) (10) — — (21) Balance at November 30, 2023 $ 15 $ — $ 62 $ 11 $ 88 O During the three months ended November 30, 2023, VillageMD approved the full or partial exit from 6 markets, including the closure of approximately 70 clinics in fiscal 2024. As a result, long-lived and intangible assets of $124 million were impaired. The impairment charge was recorded in Selling, general and administrative expenses within the Consolidated Condensed Statements of Earnings.

Leases

Leases	3 Months Ended
	Nov. 30, 2023
Leases [Abstract]
Leases	Leases The Company leases certain retail stores, clinics, warehouses, distribution centers, office space, land, and equipment. Initial terms for leased premises in the U.S. are typically 10 to 25 years, followed by additional terms containing renewal options at five-year intervals, and may include rent escalation clauses. Non-U.S. leases are typically for shorter terms and may include cancellation clauses or renewal options. Lease commencement is the date the Company has the right to control the property. The Company recognizes operating lease rent expense on a straight line basis over the lease term. In addition to minimum fixed rentals, some leases provide for contingent rentals based on sales volume. Supplemental balance sheet information related to leases was as follows (in millions): Balance sheet supplemental information: November 30, 2023 August 31, 2023 Operating leases: Operating lease right-of-use assets $ 21,708 $ 21,667 Operating lease obligations - current $ 2,350 $ 2,347 Operating lease obligations - non-current 22,132 22,124 Total operating lease obligations $ 24,482 $ 24,472 Finance leases: Right-of-use assets included in: Property, plant and equipment, net $ 663 $ 678 Lease obligations included in: Accrued expenses and other liabilities $ 58 $ 57 Other non-current liabilities 908 919 Total finance lease obligations $ 966 $ 976 Supplemental income statement information related to leases was as follows (in millions): Three months ended November 30, Statement of earnings supplemental information: 2023 2022 Operating lease cost Fixed $ 868 $ 813 Variable 1 214 192 Finance lease cost Amortization $ 19 $ 11 Interest 13 12 Sublease income 2 $ 28 $ 29 Impairment of right-of-use assets 49 67 Gain on sale-leaseback transactions 2 U.S. Retail Pharmacy $ 160 $ 172 International 3 — 17 Total gain on sale-leaseback 2 $ 160 $ 189 1 Includes real estate property taxes, common area maintenance, insurance and rental payments based on sales volume. 2 Recorded in Selling, general and administrative expenses within the Consolidated Condensed Statements of Earnings. 3 Includes gain on sale-leaseback of $17 million related to the optimization of the Germany wholesale business warehouse locations as part of acquisition integration activities in the three months ended November 30, 2022. Other supplemental information was as follows (in millions): Three months ended November 30, Other supplemental information: 2023 2022 Cash paid for amounts included in the measurement of lease obligations Operating cash flows from operating leases $ 924 $ 828 Operating cash flows from finance leases 13 11 Financing cash flows from finance leases 14 10 Total $ 951 $ 849 Right-of-use assets obtained in exchange for new lease obligations Operating leases $ 679 $ 602 Finance leases 5 1 Total $ 685 $ 603 Weighted average lease term and discount rate for real estate leases were as follows: Weighted average lease terms and discount rates: November 30, 2023 August 31, 2023 Weighted average remaining lease term in years Operating leases 9.6 9.6 Finance leases 17.1 17.4 Weighted average discount rate Operating leases 5.43 % 5.35 % Finance leases 5.26 % 5.25 % The aggregate future lease payments for operating and finance leases as of November 30, 2023 were as follows (in millions): Future lease payments (fiscal years): Finance lease Operating lease 1,2 2024 (Remaining period) $ 84 $ 2,763 2025 106 3,629 2026 102 3,552 2027 100 3,466 2028 91 3,311 2029 85 3,063 Later 880 12,004 Total undiscounted minimum lease payments $ 1,447 $ 31,787 Less: Present value discount 480 7,305 Lease liability $ 966 $ 24,482 1. Total undiscounted minimum lease payments include approximately $3.8 billion of payments related to optional renewal periods that have not been contractually exercised, but are reasonably certain of being exercised. 2. Total undiscounted minimum lease payments exclude sublease rental income of approximately $614 million due to the Company under non-cancelable sublease terms.
Leases	Leases The Company leases certain retail stores, clinics, warehouses, distribution centers, office space, land, and equipment. Initial terms for leased premises in the U.S. are typically 10 to 25 years, followed by additional terms containing renewal options at five-year intervals, and may include rent escalation clauses. Non-U.S. leases are typically for shorter terms and may include cancellation clauses or renewal options. Lease commencement is the date the Company has the right to control the property. The Company recognizes operating lease rent expense on a straight line basis over the lease term. In addition to minimum fixed rentals, some leases provide for contingent rentals based on sales volume. Supplemental balance sheet information related to leases was as follows (in millions): Balance sheet supplemental information: November 30, 2023 August 31, 2023 Operating leases: Operating lease right-of-use assets $ 21,708 $ 21,667 Operating lease obligations - current $ 2,350 $ 2,347 Operating lease obligations - non-current 22,132 22,124 Total operating lease obligations $ 24,482 $ 24,472 Finance leases: Right-of-use assets included in: Property, plant and equipment, net $ 663 $ 678 Lease obligations included in: Accrued expenses and other liabilities $ 58 $ 57 Other non-current liabilities 908 919 Total finance lease obligations $ 966 $ 976 Supplemental income statement information related to leases was as follows (in millions): Three months ended November 30, Statement of earnings supplemental information: 2023 2022 Operating lease cost Fixed $ 868 $ 813 Variable 1 214 192 Finance lease cost Amortization $ 19 $ 11 Interest 13 12 Sublease income 2 $ 28 $ 29 Impairment of right-of-use assets 49 67 Gain on sale-leaseback transactions 2 U.S. Retail Pharmacy $ 160 $ 172 International 3 — 17 Total gain on sale-leaseback 2 $ 160 $ 189 1 Includes real estate property taxes, common area maintenance, insurance and rental payments based on sales volume. 2 Recorded in Selling, general and administrative expenses within the Consolidated Condensed Statements of Earnings. 3 Includes gain on sale-leaseback of $17 million related to the optimization of the Germany wholesale business warehouse locations as part of acquisition integration activities in the three months ended November 30, 2022. Other supplemental information was as follows (in millions): Three months ended November 30, Other supplemental information: 2023 2022 Cash paid for amounts included in the measurement of lease obligations Operating cash flows from operating leases $ 924 $ 828 Operating cash flows from finance leases 13 11 Financing cash flows from finance leases 14 10 Total $ 951 $ 849 Right-of-use assets obtained in exchange for new lease obligations Operating leases $ 679 $ 602 Finance leases 5 1 Total $ 685 $ 603 Weighted average lease term and discount rate for real estate leases were as follows: Weighted average lease terms and discount rates: November 30, 2023 August 31, 2023 Weighted average remaining lease term in years Operating leases 9.6 9.6 Finance leases 17.1 17.4 Weighted average discount rate Operating leases 5.43 % 5.35 % Finance leases 5.26 % 5.25 % The aggregate future lease payments for operating and finance leases as of November 30, 2023 were as follows (in millions): Future lease payments (fiscal years): Finance lease Operating lease 1,2 2024 (Remaining period) $ 84 $ 2,763 2025 106 3,629 2026 102 3,552 2027 100 3,466 2028 91 3,311 2029 85 3,063 Later 880 12,004 Total undiscounted minimum lease payments $ 1,447 $ 31,787 Less: Present value discount 480 7,305 Lease liability $ 966 $ 24,482 1. Total undiscounted minimum lease payments include approximately $3.8 billion of payments related to optional renewal periods that have not been contractually exercised, but are reasonably certain of being exercised. 2. Total undiscounted minimum lease payments exclude sublease rental income of approximately $614 million due to the Company under non-cancelable sublease terms.

Equity method investments

Equity method investments	3 Months Ended
	Nov. 30, 2023
Equity Method Investments and Joint Ventures [Abstract]
Equity method investments	Equity method investments Equity method investments were as follows (in millions, except percentages): November 30, 2023 August 31, 2023 Carrying value Ownership percentage Carrying value Ownership percentage Cencora $ 2,430 15% $ 2,534 16% Others 970 8% - 50% 963 8% - 50% Total $ 3,400 $ 3,497 Cencora investment As of November 30, 2023 and August 31, 2023, the Company owned 30.5 million and 31.8 million shares of Cencora, Inc. (“Cencora”) common stock, respectively, representing approximately 15.3% and 15.9% of its outstanding common stock based on the share count publicly reported by Cencora in its most recent filings with the SEC. During the three months ended November 30, 2023 and 2022, the Company sold shares of Cencora common stock for total consideration of approximately $250 million and $2.0 billion, respectively. These transactions resulted in the Company recording pre-tax gains of $139 million and $969 million, respectively, in Other (expense) income, net within the Consolidated Condensed Statements of Earnings, including $8 million and $110 million of losses, respectively, reclassified from within Accumulated other comprehensive loss in the Consolidated Condensed Balance Sheets. As of November 30, 2023 and August 31, 2023 the Company has pledged 20.0 million and 17.3 million shares of Cencora common stock, respectively, as collateral upon entering into variable prepaid forward (“VPF”) transactions. See Note 8. Financial instruments for further information. The Company accounts for its equity investment in Cencora using the equity method of accounting, with the net earnings attributable to the Company’s investment being classified within the operating income of its U.S. Retail Pharmacy segment. Due to the timing and availability of financial information of Cencora, the Company accounts for this equity method investment on a financial reporting lag of two months. Equity earnings from Cencora are reported as a separate line item in the Consolidated Condensed Statements of Earnings. The Level 1 fair market value of the Company’s equity investment in Cencora common stock at November 30, 2023 and August 31, 2023 was $6.2 billion and $5.6 billion, respectively. As of November 30, 2023 the carrying value of the Company’s investment in Cencora exceeded its proportionate share of the net assets of Cencora by $2.4 billion. This premium of $2.4 billion was recognized as part of the carrying value in the Company’s equity investment in Cencora. The difference is primarily related to goodwill and the fair value of Cencora intangible assets. Summarized financial information Summarized financial information for the Company’s equity method investment in Cencora is as follows (in millions): Three months ended November 30, Statements of earnings 2023 2022 Sales $ 68,922 $ 61,174 Gross profit 2,211 1,998 Net earnings 351 295 Share of earnings from equity method investments 42 53 Other investments

Goodwill and other intangible a

Goodwill and other intangible assets	3 Months Ended
	Nov. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and other intangible assets	Goodwill and other intangible assets The changes in the carrying amount of goodwill by reportable segment are as follows (in millions): Goodwill roll forward: U.S. Retail Pharmacy International U.S. Healthcare Walgreens Boots Alliance, Inc. August 31, 2023 $ 10,947 $ 1,378 $ 15,863 $ 28,187 Adjustments 1 — — 21 21 Cumulative translation adjustments and other — (17) (8) (25) November 30, 2023 $ 10,947 $ 1,361 $ 15,876 $ 28,184 1 Includes measurement period adjustments related to VillageMD's fiscal 2023 acquisitions. See Note 2. Acquisitions and other investments for further information. The carrying amount and accumulated amortization of intangible assets consist of the following (in millions): Intangible assets: November 30, 2023 August 31, 2023 Gross amortizable intangible assets Customer relationships and loyalty card holders 1 $ 4,630 $ 4,658 Provider networks 3,148 3,202 Trade names and trademarks 2,296 2,300 Developed technology 469 469 Others 113 137 Total gross amortizable intangible assets $ 10,656 $ 10,767 Accumulated amortization Customer relationships and loyalty card holders 1 $ 1,825 $ 1,784 Provider networks 281 233 Trade names and trademarks 439 401 Developed technology 162 143 Others 52 48 Total accumulated amortization 2,759 2,609 Total amortizable intangible assets, net $ 7,898 $ 8,158 Indefinite-lived intangible assets Trade names and trademarks $ 4,566 $ 4,650 Pharmacy licenses 813 828 Total indefinite-lived intangible assets $ 5,380 $ 5,477 Total intangible assets, net $ 13,278 $ 13,635 1 Includes purchased prescription files. Amortization expense for intangible assets was $240 million and $159 million for the three months ended November 30, 2023 and 2022, respectively. Estimated future annual amortization expense for the next five fiscal years for intangible assets recorded at November 30, 2023 is as follows (in millions): 2024 (Remaining period) 2025 2026 2027 2028 2029 Estimated annual amortization expense $ 702 $ 901 $ 865 $ 783 $ 706 $ 662

Debt

Debt	3 Months Ended
	Nov. 30, 2023
Debt Disclosure [Abstract]
Debt	Debt Debt carrying values are presented net of unamortized discount and debt issuance costs, where applicable, and foreign currency denominated debt is translated to the U.S. dollar using the spot rates as of the balance sheet date. Debt consists of the following (all amounts are presented in millions of U.S. dollars and debt issuances are denominated in U.S. dollars, unless otherwise noted): November 30, 2023 August 31, 2023 Short-term debt Commercial paper 1 $ 128 $ — Credit facilities 1 November 2021 DDTL due November 2024 290 — $850 million note issuance 1 0.9500% unsecured notes due 2023 — 850 $8 billion note issuance 1 3.800% unsecured notes due 2024 1,156 — Other 2 96 68 Total short-term debt $ 1,670 $ 917 Long-term debt Credit facilities 1 November 2021 DDTL due November 2024 $ — $ 289 December 2022 DDTL due January 2026 999 999 August 2023 DDTL due November 2026 999 — $1.5 billion note issuance 1 3.200% unsecured notes due 2030 498 498 4.100% unsecured notes due 2050 762 793 $6 billion note issuance 1 3.450% unsecured notes due 2026 1,444 1,444 4.650% unsecured notes due 2046 313 318 $8 billion note issuance 1 3.800% unsecured notes due 2024 — 1,156 4.500% unsecured notes due 2034 301 301 4.800% unsecured notes due 2044 805 869 £700 million note issuance 1 3.600% unsecured Pound Sterling notes due 2025 375 381 €750 million note issuance 1 2.125% unsecured Euro notes due 2026 819 814 $4 billion note issuance 3 4.400% unsecured notes due 2042 255 263 Other 2 15 20 Total long-term debt, less current portion $ 7,585 $ 8,145 1 Notes, borrowings under credit facilities and commercial paper are unsecured and unsubordinated debt obligations of the Company and rank equally in right of payment with all other unsecured and unsubordinated indebtedness of the Company from time to time outstanding. 2 Other debt represents a mix of fixed and variable rate debt with various maturities and working capital facilities denominated in various currencies. 3 Notes are senior debt obligations of Walgreen Co. $850 million Note Issuance On November 17, 2021, the Company issued, in an underwritten public offering, $850 million of 0.95% notes due 2023. The notes contain a call option which allows for the notes to be repaid, in full or in part, at 100% of the principal amount of the notes to be redeemed, in each case plus accrued and unpaid interest. On November 17, 2023, the Company repaid the note in full. Credit facilities August 2023 Revolving Credit Agreement On August 9, 2023, the Company entered into a $2.25 billion unsecured three-year revolving credit facility (the “August 2023 Revolving Credit Agreement”). Interest on borrowings under the revolving credit facility accrues at applicable margins based on the Company's Index Debt Rating by Moody’s or S&P and ranges from 75 basis points to 150 basis points over specified benchmark rates for Secured Overnight Financing Rate (“SOFR”) loans, as applicable. Additionally, the Company pays commitment fees to maintain the availability under the August 2023 Revolving Credit Agreement at applicable fee rates based upon certain criteria at an annual rate on the unutilized portion of the total credit commitment. The August 2023 Revolving Credit Agreement's termination date is August 9, 2026, or earlier, subject to the Company's discretion to terminate the agreement. As of November 30, 2023, there were no borrowings outstanding under the August 2023 Revolving Credit Agreement. August 2023 Delayed Draw Term Loan On August 9, 2023, the Company entered into a $1 billion senior unsecured delayed draw term loan credit agreement (the “August 2023 DDTL”). Interest on borrowings under the August 2023 DDTL accrues at applicable margins based on the Company’s Index Debt Rating by Moody’s or S&P and ranges from 75 basis points to 150 basis points over specified benchmark rates for SOFR loans, as applicable. The August 2023 DDTL was drawn for general corporate purposes. The August 2023 DDTL matures on November 17, 2026. As of November 30, 2023, there was $1 billion in borrowing outstanding under the August 2023 DDTL. Amounts borrowed under the August 2023 DDTL that are repaid or prepaid may not be reborrowed. December 2022 Delayed Draw Term Loan On December 19, 2022, the Company entered into a $1.0 billion senior unsecured delayed draw term loan credit agreement (the “December 2022 DDTL”). Interest on borrowings under the December 2022 DDTL accrues at applicable margins based on the Company’s Index Debt Rating by Moody’s or S&P and ranges from 87.5 basis points to 150 basis points over specified benchmark rates for SOFR loans, as applicable. The December 2022 DDTL was drawn for the purpose of funding the consideration due for the purchase of Summit and paying fees and expenses related to it. The December 2022 DDTL matures on January 3, 2026. As of November 30, 2023, there was $1 billion in borrowing outstanding under the December 2022 DDTL. Amounts borrowed under the December 2022 DDTL that are repaid or prepaid may not be reborrowed. June 2022 Revolving Credit Agreements On June 17, 2022, the Company entered into a $3.5 billion unsecured five-year revolving credit facility and a $1.5 billion unsecured 18-month revolving credit facility, with designated borrowers from time to time party thereto and lenders from time to time party thereto (the “2022 Revolving Credit Agreements”). Interest on borrowings under the revolving credit facilities accrues at applicable margins based on the Company's Index Debt Rating by S&P or Moody’s and ranges from 80 basis points to 150 basis points over specified benchmark rates for SOFR loans, as applicable. Additionally, the Company pays commitment fees to maintain the availability under the revolving credit facility at applicable fee rates based upon certain criteria at an annual rate on the unutilized portion of the total credit commitment. The five-year facility’s termination date is June 17, 2027, or earlier, subject to the Company's discretion to terminate the agreement. The 18-month facility’s termination date was December 15, 2023, or earlier, subject to the Company's discretion to terminate the agreement. On August 9, 2023 the Company terminated the 18 -month facility under the 2022 Revolving Credit Agreements. All outstanding obligations under the 18 -month revolving credit facility have been paid and satisfied in full. As of November 30, 2023 , there were no borrowings outstanding under the five-year r evolving credit facility. November 2021, Delayed Draw Term Loan On November 15, 2021, the Company entered into a $5.0 billion senior unsecured multi-tranche delayed draw term loan credit facility, (the “November 2021 DDTL”) consisting of (i) a 364-day senior unsecured delayed draw term loan facility in an aggregate principal amount of $2.0 billion (the “364-day loan”), (ii) a two-year senior unsecured delayed draw term loan facility in an aggregate principal amount of $2.0 billion (the “two-year loan”) and (iii) a three-year senior unsecured delayed draw term loan facility in an aggregate principal amount of $1.0 billion (the “three-year loan”). Borrowings under the November 2021 DDTL bear interest at a fluctuating rate per annum equal to SOFR, plus an applicable margin. The applicable margins for the 364-day and two-year loans were 0.75% and 0.88%, respectively. The applicable margin for the three-year loan is 1.05%. An aggregate amount of $3.0 billion or more of the November 2021 DDTL was drawn for the purpose of funding the purchase of the increased equity interest in VillageMD, and paying fees and expenses related to the foregoing, with the remainder used for general corporate purposes. In fiscal 2023, the Company repaid the 364-day and two-year loans in full. The maturity date on the three-year loan is November 24, 2024. As of November 30, 2023, there were $290 million in borrowings outstanding under the November 2021 DDTL. Amounts borrowed under the November 2021 DDTL and repaid or prepaid may not be reborrowed. Debt covenants Each of the Company’s credit facilities described above contain a covenant to maintain, as of the last day of each fiscal quarter, a ratio of consolidated debt to total capitalization not to exceed 0.60:1.00, subject to increase in certain circumstances set forth in the applicable credit agreement. The credit facilities contain various other customary financial covenants. As of November 30, 2023, the Company was in compliance with all such applicable financial covenants. Commercial paper The Company periodically borrows under its commercial paper program and may borrow under it in future periods. As of November 30, 2023, the Company's outstanding commercial paper is $128 million and had a weighted average interest rate of 6.22%. As of August 31, 2023 the Company had no borrowings outstanding under the commercial paper program. Interest Interest paid by the Company was approximately $177 million and $160 million for the three months ended November 30, 2023 and 2022, respectively. Credit ratings The Company’s senior unsecured debt ratings were lowered to BBB- with a negative outlook by Standard and Poor’s in October 2023 and Ba2 (below investment grade) with a stable outlook by Moody’s in December 2023. The reduction in the Company's credit ratings has limited impact to the cost of interest on existing debt, but has minimally increased borrowing margins under certain credit facilities that are tied to ratings grids or similar terms. The Company's current credit ratings significantly reduce the Company's ability to issue commercial paper, may increase the cost of new financing for the Company, and may decrease access to credit and debt capital markets. As of November 30, 2023, the Company had an aggregate borrowing capacity under committed revolving credit facilities of $5.8 billion, with no funds drawn under these facilities.

Financial instruments

Financial instruments	3 Months Ended
	Nov. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial instruments	Financial instruments The Company uses derivative instruments to hedge its exposure to market risks, including interest rate and currency risks, arising from operating and financing risks. The Company has non-U.S. dollar denominated net investments and uses foreign currency denominated financial instruments, specifically foreign currency derivatives and foreign currency denominated debt, to hedge its foreign currency risk. The Company economically hedges a portion of its exposure to equity price risk related to its investment in Cencora through VPF derivative contracts. The notional amounts and fair value of derivative instruments outstanding were as follows (in millions): November 30, 2023 Notional Fair Location in Consolidated Condensed Balance Sheets Derivatives designated as hedges: Foreign currency forwards $ 1 $ — Other current assets Cross currency interest rate swaps 350 12 Other current assets Cross currency interest rate swaps 300 18 Other non-current assets Foreign currency forwards 778 6 Other current liabilities Cross currency interest rate swaps 101 1 Other current liabilities Foreign currency forwards 1 — Other non-current liabilities Derivatives not designated as hedges: Foreign currency forwards $ 352 $ 1 Other current assets Total return swaps 186 8 Other current assets Foreign currency forwards 3,454 19 Other current liabilities Variable prepaid forward contracts 3,726 3,338 Other non-current liabilities August 31, 2023 Notional Fair Location in Consolidated Condensed Balance Sheets Derivatives designated as hedges: Foreign currency forwards $ 31 $ 1 Other current assets Cross currency interest rate swaps 650 28 Other non-current assets Foreign currency forwards 805 2 Other current liabilities Cross currency interest rate swaps 102 2 Other current liabilities Foreign currency forwards 4 — Other non-current liabilities Derivatives not designated as hedges: Foreign currency forwards $ 3,139 $ 6 Other current assets Total return swaps 168 1 Other current assets Foreign currency forwards 817 2 Other current liabilities Total return swaps 26 1 Other current liabilities Variable prepaid forward contracts 3,195 2,548 Other non-current liabilities Net investment hedges The Company uses cross currency interest rate swaps and foreign currency forward contracts to hedge net investments in subsidiaries with non-U.S. dollar functional currencies. For qualifying net investment hedges, changes in the fair value of the derivatives are recorded in Cumulative translation adjustments within Accumulated other comprehensive loss in the Consolidated Condensed Balance Sheets. Cash flow hedges The Company may use foreign currency forwards and interest rate swaps to hedge the variability in forecasted transactions and cash flows of certain floating-rate debt. For qualifying cash flow hedges, changes in the fair value of the derivatives are recorded in Unrealized gain (loss) on cash flow hedges in Accumulated other comprehensive loss within the Consolidated Condensed Balance Sheets, and released to the Consolidated Condensed Statements of Earnings when the hedged cash flows affect earnings. Derivatives not designated as hedges The Company enters into derivative transactions that are not designated as accounting hedges. These derivative instruments are economic hedges of foreign currency risks and equity price risk. The Company also utilizes total return swaps to economically hedge variability in compensation charges related to certain deferred compensation obligations. The Company entered into VPF transactions with third-party financial institutions and received upfront prepayments related to the forward sale of shares of Cencora common stock. The upfront prepayments are recorded within Other non-current liabilities in the Consolidated Condensed Balance Sheets as derivatives. The Company has pledged shares of Cencora common stock as collateral upon entering into the VPF transactions. The VPF transactions provide the Company with current liquidity while allowing it to maintain voting and dividend rights in the Cencora common stock, as well as the ability to participate in future stock price appreciation during the term of the contracts up to a cap price specified in the contracts. The VPF transactions are expected to settle per their respective forward settlement dates, at which time the Company will be obligated, unless it elects to settle otherwise as described below, to deliver the full number of shares of Cencora common stock specified in the contracts to settle the agreements. The Company may receive additional cash payments to be determined based on the price of the Cencora common stock at the forward settlement dates relative to the forward floor and cap price specified in the contracts. Subject to certain conditions, the Company may elect to net settle the contract by delivery of shares (or payment of the cash value thereof) in lieu of receiving any additional cash. The aggregate number of Cencora shares to be delivered in connection with the VPF transactions will not exceed the shares subject to forward sale. The terms of the VPF transactions were as follows (in millions): Transaction date Shares pledged and maximum shares subject to forward sale Prepayment amount Forward settlement date May 11, 2023 4.6 $ 644 Fourth quarter, fiscal 2025 June 15, 2023 2.2 325 Third quarter, fiscal 2025 August 3, 2023 5.3 801 First quarter, fiscal 2026 August 4, 2023 5.3 797 Third quarter, fiscal 2026 November 9, 2023 2.7 424 Fourth quarter, fiscal 2026 20.0 $ 2,991 The income (expenses) due to changes in fair value of derivative instruments were recognized in the Consolidated Condensed Statements of Earnings as follows (in millions): Three months ended November 30, Location in Consolidated Condensed Statements of Earnings 2023 2022 Total return swap Selling, general and administrative expenses $ (1) $ 4 Foreign currency forwards Other (expense) income, net 1 59 (18) Variable prepaid forward Other (expense) income, net (366) — 1. Excludes remeasurement gains and losses on economically hedged assets and liabilities. Derivatives credit risk Counterparties to derivative financial instruments expose the Company to credit-related losses in the event of counterparty nonperformance, and the Company regularly monitors the credit worthiness of each counterparty. The Company and its counterparties are subject to collateral requirements for certain derivative instruments which mitigates credit risk for both parties. Derivatives offsetting The Company does not offset the fair value amounts of derivative instruments subject to master netting agreements in the Consolidated Condensed Balance Sheets.

Fair value measurements

Fair value measurements	3 Months Ended
	Nov. 30, 2023
Fair Value Disclosures [Abstract]
Fair value measurements	Fair value measurements The Company measures certain assets and liabilities in accordance with Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements and Disclosures, which defines fair value as the price that would be received for an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. In addition, it establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels: Level 1 - Quoted prices in active markets that are accessible at the measurement date for identical assets and liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2 - Observable inputs other than quoted prices in active markets. Level 3 - Unobservable inputs for which there is little or no market data available. The fair value hierarchy gives the lowest priority to Level 3 inputs. Assets and liabilities measured at fair value on a recurring basis were as follows (in millions): November 30, 2023 Level 1 Level 2 Level 3 Assets : Money market funds 1 $ 5 $ 5 $ — $ — Cross currency interest rate swaps 2 31 — 31 — Foreign currency forwards 3 1 — 1 — Investments in equity securities 4 18 18 — — Investments in debt securities 5 109 — 109 — Total return swaps 8 — 8 — Liabilities : Variable prepaid forward 6 $ 3,338 $ — $ — $ 3,338 Foreign currency forwards 3 24 — 24 — Cross currency interest rate swaps 2 1 — 1 — August 31, 2023 Level 1 Level 2 Level 3 Assets : Money market funds 1 $ 11 $ 11 $ — $ — Cross currency interest rate swaps 2 28 — 28 — Foreign currency forwards 3 6 — 6 — Investments in equity securities 4 17 17 — — Investments in debt securities 5 15 — 15 — Total return swaps 1 — 1 — Liabilities : Variable prepaid forward 6 $ 2,548 $ — $ — $ 2,548 Foreign currency forwards 3 5 — 5 — Total return swaps 1 — 1 — Cross currency interest rate swaps 2 2 — 2 — 1 Money market funds are valued at the closing price reported by the fund sponsor and classified as Cash and cash equivalents within the Consolidated Condensed Balance Sheets. 2 The fair value of cross currency interest rate swaps is calculated by discounting the estimated future cash flows based on the applicable observable yield curves. See Note 8. Financial instruments, for additional information. 3 The fair value of forward currency contracts is estimated by discounting the difference between the contractual forward price and the current available forward price for the residual maturity of the contract using observable market rates. See Note 8. Financial instruments, for additional information. 4 Fair values of quoted investments are based on current bid prices as of November 30, 2023 and August 31, 2023. 5 Includes investments in Treasury debt securities. 6 The fair value of the derivative was derived from a Black-Scholes valuation. The inputs used in valuing the derivative included observable inputs such as the floor and cap prices of the VPF, dividend yield of Cencora shares, risk free interest rate, and contractual term of the instrument, as well as unobservable inputs such as implied volatility of Cencora shares. The implied volatility ranged from 24.7% - 27.8% for the lower strike and 19.3% - 20.8% for the upper strike as of November 30, 2023, and 23.2% - 24.7% for the lower strike and 18.1% - 19.1% for the upper strike as of August 31, 2023. There were no transfers between Levels for the three months ended November 30, 2023. The roll forward of the fair value of the VPF derivatives associated with the forward sale of shares of Cencora common stock, classified as Level 3, is as follows (in millions): Three months ended November 30, 2023 Opening balance $ (2,548) VPF derivative additions (424) Unrealized losses recorded in Other (expense) income, net (366) Ending balance $ (3,338) The Company reports its debt instruments under the guidance of ASC Topic 825, Financial Instruments, which requires disclosure of the fair value of the Company’s debt in the footnotes to the Consolidated Condensed Financial Statements. As of November 30, 2023 the carrying amounts and estimated fair values of long term notes outstanding including the current portion were $6.7 billion and $5.8 billion, respectively. The fair values of the notes outstanding are Level 1 fair value measures and determined based on quoted market price and translated at the November 30, 2023 rate, as applicable. The fair values and carrying values of these issuances do not include notes that have been redeemed or repaid as of November 30, 2023. The carrying value of the Company's commercial paper, credit facilities, accounts receivable and trade accounts payable approximated their respective fair values due to their short-term nature.

Commitments and contingencies

Commitments and contingencies	3 Months Ended
	Nov. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	Commitments and contingencies The Company is involved in legal proceedings arising in the normal course of its business, including litigation, arbitration and other claims, and investigations, inspections, subpoenas, audits, claims, inquiries and similar actions by governmental authorities in pharmacy, healthcare, tax and other areas. Some of these proceedings may be class actions, and some involve claims for large or indeterminate amounts, including punitive or exemplary damages, and they may remain unresolved for several years. Legal proceedings in general, and securities, class action and multi-district litigation, in particular, can be expensive and disruptive. From time to time, the Company is also involved in legal proceedings as a plaintiff involving antitrust, tax, contract, intellectual property and other matters. Gain contingencies, if any, are recognized when they are realized. The Company is subject to extensive regulation by national, state and local government agencies in the U.S. and other countries in which it operates. The Company’s business, compliance and reporting practices are subject to intensive scrutiny under applicable regulation, including review or audit by regulatory authorities. As a result, the Company regularly is the subject of government actions of the types described herein. The Company also may be named from time to time in qui tam actions initiated by private parties. In such an action, a private party purports to act on behalf of federal or state governments, alleges that false claims have been submitted for payment by the government and may receive an award if its claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on its own purporting to act on behalf of the government. The results of legal proceedings, including government investigations, are often uncertain and difficult to predict, and the costs incurred in these matters can be substantial, regardless of the outcome. In addition, as a result of governmental investigations or proceedings, the Company may be subject to damages, civil or criminal fines or penalties, or other sanctions, including the possible suspension or loss of licensure and suspension or exclusion from participation in government programs. The Company describes below certain proceedings against the Company in which the amount of loss could be material. The Company accrues for legal claims when, and to the extent that, the amount or range of probable loss can be reasonably estimated. The Company believes there are meritorious defenses in each of these proceedings, and it intends to defend each case vigorously, but there can be no assurance as to the ultimate outcome. With respect to litigation and other legal proceedings where the Company has determined a material loss is reasonably possible, except as otherwise disclosed, the Company is not able to make a reasonable estimate of the amount or range of loss that is reasonably possible above any accrued amounts in these proceedings, due to various reasons, including: existence of factual and legal arguments that, if successful, will eliminate or sharply reduce the possibility of loss; lack of sufficient information about the arguments and the evidence plaintiffs will advance with respect to their damages; some of the cases have been stayed; certain proceedings present novel and complex questions of public policy; legal and factual determinations and judicial and governmental procedure; the large number of parties involved; and the inherent uncertainties related to such litigation. Securities Claims Relating to Rite-Aid Merger On December 11, 2017, purported Rite-Aid shareholders filed an amended complaint in a putative class action lawsuit in the U.S. District Court for the Middle District of Pennsylvania (the “M.D. Pa. class action”) arising out of transactions contemplated by the merger agreement between the Company and Rite-Aid. The amended complaint alleges that the Company and certain of its officers made false or misleading statements regarding the transactions. Fact and expert discovery have concluded. The Court denied both plaintiffs’ partial motion for summary judgement and the Company’s motion for summary judgment on March 31, 2023. Trial is scheduled for January 29, 2024. On August 23, 2023, the Company, the other defendants in the M.D. Pa. class action, and the lead plaintiffs entered into a binding agreement to settle all claims in the M.D. Pa. class action. The settlement of approximately $193 million provides for the dismissal of the M.D. Pa. class action with prejudice. Defendants admitted no liability and denied all allegations of wrongdoing. The Company is fully accrued for this matter.. The court granted preliminary approval of the settlement on October 23, 2023 and set a date of February 7, 2024 for the final settlement approval hearing. In October and December 2020, two separate purported Rite-Aid shareholders filed actions in the same court opting out of the class in the M.D. Pa. class action and making nearly identical allegations as those in the M.D. Pa. class action (the “Opt-out Actions”). The related trial has been scheduled for June 10, 2024. On March 19, 2021, a putative shareholder filed a derivative suit in the District Court of Delaware (Clem v. Skinner, et. al, 21-CV-406 Del Dist. Ct.) against certain current and former Walgreens directors and officers, seeking damages based on alleged breaches of fiduciary duty and seeking contribution under Section 21D of the Exchange Act of 1934, as amended, in connection with the M.D. Pa. class action. The plaintiff's allegations in this derivative suit concern the same public statements at issue in the M.D. Pa. class action. The case had been stayed since its inception given the pending M.D. Pa. class action. The stay was lifted following the Court's rulings on summary judgment motions in the M.D. Pa. class action. Claims Relating to Opioid Abuse On May 5, 2022, the Company announced that it had entered into a settlement agreement with the State of Florida to resolve all claims related to the distribution and dispensing of prescription opioid medications across the Company’s pharmacies in the State of Florida. This settlement agreement was not an admission of liability or wrong-doing and resolved all pending and future opioid litigation by state and government subdivisions in the State of Florida. The settlement amount of $683 million includes $620 million in remediation payments, which will be paid to the State of Florida in equal installments over 18 years, and will be applied as opioid remediation, as well as a one-time payment of $63 million for attorneys’ fees. In fiscal 2022, the Company recorded a $683 million liability associated with this settlement. On November 2, 2022, the Company announced that it had agreed to financial amounts and payment terms as part of settlement frameworks (the “Settlement Frameworks”) that had the potential to resolve a substantial majority of opioid-related lawsuits filed against the Company by the attorneys general of participating states and political subdivisions (the “Settling States”) and litigation brought by counsel for tribes. Under the Settlement Frameworks with the Settling States and counsel for tribes, the Company announced that it expected to settle all opioid claims against it by such Settling States, their participating political subdivisions, and participating tribes for up to approximately $4.8 billion and $155 million, respectively in remediation payments to be paid out over 15 years. The Settlement Frameworks provided for the payment of up to approximately $754 million in attorneys’ fees and costs over 6 years beginning in year two of the Settlement Frameworks. The Settlement Frameworks included no admission of wrongdoing or liability by the Company. As of November 30, 2022, the Company concluded that Settlement Frameworks discussions had advanced to a stage where a broad settlement of opioid claims by Settling States was probable, and for which the related loss was reasonably estimable. As a result of those conclusions and the Company’s ongoing assessment of other opioid-related claims, the Company recorded a $6.5 billion liability associated with the Settlement Frameworks and other opioid-related claims and litigation settlements during the three months ended November 30, 2022. The settlement accrual was reflected in the Consolidated Condensed Statements of Earnings within Selling, general and administrative expenses as part of the U.S. Retail Pharmacy segment. On December 9, 2022, the Company committed the Settlement Frameworks to a proposed settlement agreement (the “Proposed Settlement Agreement”) that was contingent on (1) a sufficient number of Settling States, including those that had not sued, agreeing to the Proposed Settlement Agreement following a sign-on period, and (2) following a notice period, a sufficient number of political subdivisions within Settling States, including those that had not sued, agreeing to the Proposed Settlement Agreement (or otherwise having their claims foreclosed). On June 8, 2023 the Company informed the Settling States that there was sufficient State participation, sufficient Subdivision participation, and sufficient resolution of the claims of Litigating Subdivisions in the Settling States to proceed with the multistate settlement. The Company has now resolved its litigation with all states, territories, tribes and 99.5% of litigating subdivisions within Settling States included in the Proposed Settlement or in separate agreements. Estimated liabilities for these settlements are fully accrued. Incentive payments to Settling States with non-participating political subdivisions are subject to reduction and those subdivisions are still entitled to pursue their claims against the Company. The Proposed Settlement Agreement became effective on August 7, 2023 (the “Multistate Settlement Agreement”). The Company will continue to vigorously defend against any litigation not covered by the Multistate Settlement Agreement, including private plaintiff litigation. The Company continues to believe it has strong legal defenses and appellate arguments in all of these cases. As of November 30, 2023, the Company has accrued a total of $6.9 billion liability associated with the Multistate Settlement Agreement and other opioid-related claims and litigation settlements, including $649 million and $6.3 billion of the estimated settlement liability in Accrued expenses and other liabilities, and Accrued litigation obligations, respectively, in the Consolidated Condensed Balance Sheets. The Company remains a defendant in multiple actions in federal courts alleging claims generally concerning the impacts of widespread opioid abuse, which have been commenced by various plaintiffs. In December 2017, the U.S. Judicial Panel on Multidistrict Litigation consolidated many of these cases in a consolidated multidistrict litigation, captioned In re National Prescription Opiate Litigation (MDL No. 2804, Case No. 17-MD-2804), which is pending in the U.S. District Court for the Northern District of Ohio (“N.D. Ohio”). The Company is a defendant in the following multidistrict litigation (MDL) bellwether cases: • Two consolidated cases in N.D. Ohio ( Cnty. of Lake, Ohio v. Purdue Pharma L.P., et al., Case No. 18-op-45032 ; Cnty. of Trumbull, Ohio v. Purdue Pharma L.P., et al ., Case No. 18-op-45079). In November 2021, the jury returned a verdict in favor of the plaintiffs as to liability, and a second trial regarding remedies took place in May 2022. In August 2022, the court entered orders providing for injunctive relief and requiring the defendants to pay $651 million over a 15-year period to fund abatement programs. The court found that the damages are subject to joint and several liability and as such made no determination as to apportionment. These decisions are currently on appeal. • Louisiana Assessors Ins. Fund v. AmerisourceBergen Drug Corp., et al., 1:18-op-46223 (M.D. La.). • Pioneer Tele, Coop. Inc. Employee Benefits Plan v. Purdue Pharma LP et al, 1:18-op-46186 (W.D. Okla.). • United Food and Comm. Workers Health and Welfare Fund of Northeastern Pennsylvania v. Purdue Pharma, LP et a l. , 1:17-op-45117 (E.D. Pa.). • Sheet Metal Workers Local No. 25 Health & Welfare Fund v. Purdue Pharma, LP et al., 1:18-op-45002 (E.D. Pa.). The Company also has been named as a defendant in multiple actions brought in state courts relating to opioid matters. Trial dates have been set in cases pending in state courts in the following states: • Maryland (Mayor and City Council of Baltimore v. Purdue Pharma L.P., et al., Case No. 24-C-18-000515, Circuit Court for Baltimore City, Baltimore, Maryland - September 2024). • Florida ( Florida Health Sciences Center, Inc., et al. v. Richard Sackler, et al ., Case No. CACE 19-018882, Seventeenth Judicial Circuit Court, Broward County, Florida - September 2025). The relief sought by various plaintiffs in these matters includes compensatory, abatement, restitution and punitive damages, as well as injunctive relief. Additionally, the Company has received from the U.S. Department of Justice (“DOJ”) and the Attorneys General of numerous states subpoenas, civil investigative demands, and other requests concerning opioid-related matters. The Company continues to communicate with the DOJ regarding purported violations of the federal Controlled Substances Act and the federal False Claims Act in dispensing prescriptions for opioids and other controlled substances at its pharmacies nationwide. On September 23, 2022, a putative shareholder filed a derivative suit in the United States District Court for the Northern District of Ohio (Vladimir Gusinsky Revocable Trust v. Pessina et. al, 22-CV-1717) against certain current and former Walgreens directors and officers, seeking damages based on alleged breaches of fiduciary duty, unjust enrichment, and violations of section 14A of the Securities and Exchange Act of 1934 in connection with oversight of risks related to opioids. A motion to dismiss for improper venue was filed on December 12, 2022. That motion was granted on September 22, 2023, and the case was dismissed without prejudice. The case was refiled on November 4, 2023, in the United States District Court for the Northern District of Illinois (Vladimir Gusinsky Revocable Trust v. Pessina et. al, 23-CV-15654). On November 14, 2023, the case was stayed to permit the parties to explore the possibility of settlement. Usual and Customary Pricing Litigation The Company is defending a number of claims, lawsuits and investigations that allege that the Company’s retail pharmacies overcharged for prescription drugs by not submitting the correct usual and customary price during the claims adjudication process. These actions have been brought by different types of plaintiffs, including insurance companies, plan members, government and private payors, based on different legal theories. On December 29, 2023, the parties reached an agreement for the settlement of the Humana dispute for $360 million which the Company fully accrued for as of November 30, 2023 and paid $150 million of the settlement amount in December 2023. Derivative Suit Relating to Insulin Pens On March 19, 2021, a putative shareholder filed a derivative suit in the Delaware Court of Chancery (Clem v. Skinner et. al, 2021-0240) against certain current and former Walgreens directors and officers, seeking damages based on alleged breaches of fiduciary duty and unjust enrichment in connection with certain allegedly false reimbursement claims to government healthcare payors related to insulin pens. On October 8, 2021, an amended complaint was filed. On December 17, 2021, the defendants moved to dismiss that amended complaint. That motion has been fully briefed and was argued on November 20, 2023.

Income taxes

Income taxes	3 Months Ended
	Nov. 30, 2023
Income Tax Disclosure [Abstract]
Income taxes	Income taxes The effective tax rate for the three months ended November 30, 2023 and 2022 was a benefit of 20.7% and 27.5%, respectively. The decrease in the effective tax rate benefit for the three months ended November 30, 2023 was primarily driven by the increase to U.S. tax expense on non-U.S. earnings and discrete tax benefits recorded in the year-ago quarter for the reduction of a valuation allowance on net deferred tax assets related to the sale of shares in Cencora and forecasted capital gains, partially offset by the impact of certain nondeductible opioid-related claims and litigation. Income taxes paid for the three months ended November 30, 2023 and 2022 were $25 million and $5 million, respectively.

Retirement benefits

Retirement benefits	3 Months Ended
	Nov. 30, 2023
Retirement Benefits [Abstract]
Retirement benefits	Retirement benefits The Company sponsors several retirement plans, including defined benefit plans, defined contribution plans and a post-retirement health plan. Defined benefit pension plans (non-U.S. plans) The Company has various defined benefit pension plans outside the U.S. The principal defined benefit pension plan is the Boots Pension Plan (the “Boots Plan”), which covers certain employees in the UK. The Boots Plan is a funded final salary defined benefit plan providing pensions and death benefits to members. The Boots Plan was closed to future accrual effective July 1, 2010, with pensions calculated based on salaries up until that date. The Boots Plan is governed by a trustee board, which is independent of the Company. The plan is subject to a full funding actuarial valuation on a triennial basis. Boots Plan Annuitization On November 23, 2023, with financial support from the Company, Boots Pensions Limited (“Trustee”), in its capacity as trustee of the Boots Plan, entered into a Bulk Purchase Annuity Agreement (“BPA”) with Legal & General Assurance Society Limited (“Legal & General”) to insure the benefits of all 53,000 of its members. Under the BPA, the Trustee will acquire a bulk annuity policy (the “Buy-In”) from Legal & General which will fund ongoing and future pension benefit payments to the Boots Plan members. The BPA is being funded through the existing Boots Plan assets, as well as incremental pre-tax contributions by the Company to the Boots Plan. The Company will accelerate approximately $210 million of already committed contributions to the Boots Plan, to be paid over the next two years. Additionally, the Company has committed to make an incremental contribution to the Boots Plan, which is expected to be approximately $760 million to $820 million, of which $375 million was paid on December 7, 2023 and the remaining amount is expected to be paid within the next two years. In conjunction with the Buy-In, the Boots Plan was amended resulting in an interim remeasurement of the Boots Plan. The remeasurement resulted in an increase in the funded status of the Boots plan of $77 million. The change resulting from the remeasurement is recorded in Accumulated other comprehensive loss within the Consolidated Condensed Balance Sheets. The BPA allows for the future potential conversion of the BPA, into a buy-out where Legal & General would assume full responsibility to directly provide pensions or other benefits to the Boots Plan members, at which time the Boots Plan can be terminated. Components of net periodic pension income for the defined benefit pension plans (in millions): Three months ended November 30, Location in Consolidated Condensed Statements of Earnings 2023 2022 Service costs Selling, general and administrative expenses $ 1 $ 1 Interest costs Other (expense) income, net 70 59 Expected returns on plan assets/other Other (expense) income, net (73) (75) Total net periodic pension income $ (3) $ (15) Defined contribution plans The principal retirement plan for U.S. employees is the Walgreen Profit-Sharing Retirement Trust, to which both the Company and participating employees contribute. The Company’s contribution is in the form of a guaranteed match which is made pursuant to the applicable plan document approved by the Walgreen Co. Board of Directors. Plan activity is reviewed periodically by certain Committees of the Walgreens Boots Alliance Board of Directors. The profit-sharing provision is an expense of $60 million and $65 million for the three months ended November 30, 2023 and 2022, respectively. The Company also has certain contract based defined contribution arrangements. The principal one is in the UK in which both the Company and participating employees contribute. The cost recognized in the Consolidated Condensed Statements of Earnings was $22 million and $20 million for the three months ended November 30, 2023 and 2022, respectively.

Accumulated other comprehensive

Accumulated other comprehensive income (loss)	3 Months Ended
	Nov. 30, 2023
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Accumulated other comprehensive income (loss)	Accumulated other comprehensive income (loss) The following is a summary of net changes in accumulated other comprehensive income (loss) (“AOCI”) by component and net of tax for the three months ended November 30, 2023 and 2022 (in millions): Pension/ post-retirement obligations Unrealized loss on cash flow hedges and other Net investment hedges Share of OCI of equity method investments Cumulative translation adjustments Total Balance at August 31, 2023 $ (698) $ (6) $ 83 $ (132) $ (2,240) $ (2,993) Other comprehensive income (loss) before reclassification adjustments 77 1 8 (28) (49) 9 Amounts reclassified from AOCI (2) 4 (4) 8 (2) 3 Tax benefit (provision) (19) — (1) 5 — (14) Net change in other comprehensive income (loss) 56 5 3 (15) (51) (2) Balance at November 30, 2023 $ (642) $ (1) $ 86 $ (147) $ (2,291) $ (2,995) Pension/ post-retirement obligations Unrealized loss on cash flow hedges and other Net investment hedges Share of OCI of equity method investments Cumulative translation adjustments Total Balance at August 31, 2022 $ (157) $ (2) $ 213 $ (254) $ (2,605) $ (2,805) Other comprehensive (loss) income before reclassification adjustments — (3) (39) (103) 22 (123) Amounts reclassified from AOCI (7) — — 110 — 103 Tax benefit (provision) 2 1 9 (3) — 9 Net change in other comprehensive (loss) income (5) (2) (29) 4 22 (11) Balance at November 30, 2022 $ (162) $ (4) $ 183 $ (250) $ (2,583) $ (2,815)

Segment reporting

Segment reporting	3 Months Ended
	Nov. 30, 2023
Segment Reporting [Abstract]
Segment reporting	Segment reporting The Company is aligned into three reportable segments: U.S. Retail Pharmacy, International and U.S. Healthcare. The operating segments have been identified based on the financial data utilized by the Company’s Chief Executive Officer (the chief operating decision maker) to assess segment performance and allocate resources among the Company’s operating segments. The chief operating decision maker uses adjusted operating income to assess segment profitability. The chief operating decision maker does not use total assets by segment to make decisions regarding resources; therefore, the total asset disclosure by segment has not been included. U.S. Retail Pharmacy The Company's U.S. Retail Pharmacy segment includes the Walgreens business which is comprised of the operations of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and its equity method investment in Cencora. Sales for the segment are principally derived from the sale of prescription drugs and a wide assortment of retail products, including health and wellness, beauty, personal care and consumables and general merchandise. International The Company's International segment consists of pharmacy-led health and beauty retail businesses outside the U.S. and a pharmaceutical wholesaling and distribution business in Germany. Pharmacy-led health and beauty retail businesses include Boots branded stores in the UK, the Republic of Ireland and Thailand, and the Benavides brand in Mexico. In the three months ended November 30, 2023, the Company completed the sale of the Farmacias Ahumada business in Chile. Sales for these businesses are principally derived from the sale of prescription drugs and health and wellness, beauty, personal care and other consumer products. U.S. Healthcare The Company’s U.S. Healthcare segment is a consumer-centric, technology-enabled healthcare business that engages consumers through a personalized, omni-channel experience across the care journey. The U.S. Healthcare segment delivers improved health outcomes and lower costs for payors and providers by delivering care through owned and partnered assets. The U.S. Healthcare segment currently consists of a majority position in VillageMD, a national provider of value-based care with primary, multi-specialty, and urgent care providers serving patients in traditional clinic settings, in patients' homes and online appointments; Shields Health Solutions Parent, LLC (“Shields”), a specialty pharmacy integrator and accelerator for hospitals; CCX Next, LLC (“CareCentrix”), a participant in the post-acute and home care management sectors, and the Walgreens Health organic business that contracts with payors and providers to deliver clinical healthcare services to their members and members’ caregivers through both digital and physical channels. The results of operations for reportable segments include procurement benefits. Corporate-related overhead costs are not allocated to reportable segments and are reported in “Corporate and Other”. The following table reflects results of operations of the Company’s reportable segments (in millions): Three months ended November 30, 2023 2022 Sales: U.S. Retail Pharmacy $ 28,944 $ 27,204 International 5,832 5,189 U.S. Healthcare 1,931 989 Walgreens Boots Alliance, Inc. $ 36,707 $ 33,382 Adjusted operating income: U.S. Retail Pharmacy $ 694 $ 1,105 International 142 116 U.S. Healthcare (96) (152) Corporate and Other (53) (56) Walgreens Boots Alliance, Inc. $ 687 $ 1,014 The following table reconciles adjusted operating income to operating loss (in millions): Three months ended November 30, 2023 2022 Adjusted operating income (Non-GAAP measure) $ 687 $ 1,014 Acquisition-related amortization (275) (330) Acquisition-related costs (163) (39) Transformational cost management (109) (138) Certain legal and regulatory accruals and settlements (82) (6,554) Adjustments to equity earnings in Cencora (50) (86) LIFO provision (48) (18) Operating loss (GAAP measure) $ (39) $ (6,151)

Sales

Sales	3 Months Ended
	Nov. 30, 2023
Revenue from Contract with Customer [Abstract]
Sales	Sales The following table summarizes the Company’s sales by segment and by major source (in millions): Three months ended November 30, 2023 2022 U.S. Retail Pharmacy Pharmacy $ 22,384 $ 20,218 Retail 6,560 6,986 Total 28,944 27,204 International Pharmacy 926 867 Retail 1,932 1,650 Wholesale 2,974 2,672 Total 5,832 5,189 U.S. Healthcare 1,931 989 Walgreens Boots Alliance, Inc. $ 36,707 $ 33,382 See Note 18. Supplemental information for further information on receivables from contracts with customers.

Related parties

Related parties	3 Months Ended
	Nov. 30, 2023
Related Party Transactions [Abstract]
Related parties	Related parties The Company has a long-term pharmaceutical distribution agreement with Cencora pursuant to which the Company sources branded and generic pharmaceutical products from Cencora. Additionally, Cencora receives sourcing services for generic pharmaceutical products. Related party transactions with Cencora (in millions): Three months ended November 30, 2023 2022 Purchases, net $ 18,311 $ 15,440 November 30, 2023 August 31, 2023 Trade accounts payable, net of receivables $ 8,154 $ 7,814

New accounting pronouncements

New accounting pronouncements	3 Months Ended
	Nov. 30, 2023
Accounting Standards Update and Change in Accounting Principle [Abstract]
New accounting pronouncements	Accounting policies Basis of presentation The Consolidated Condensed Financial Statements of Walgreens Boots Alliance, Inc. and its subsidiaries (“Walgreens Boots Alliance” or the “Company”) included herein have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. The Consolidated Condensed Financial Statements include all subsidiaries in which the Company holds a controlling interest and certain variable interest entities (“VIEs”) for which the Company is the primary beneficiary. The Company uses the equity method of accounting for equity investments in less than majority-owned companies if the investment provides the ability to exercise significant influence. All intercompany transactions have been eliminated. The Consolidated Condensed Financial Statements included herein are unaudited. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited Consolidated Condensed Financial Statements should be read in conjunction with the audited financial statements and the notes thereto included in the Walgreens Boots Alliance Annual Report on Form 10-K for the fiscal year ended August 31, 2023, as amended by Form 10-K/A for the fiscal year ended August 31, 2023 filed on November 22, 2023. The preparation of financial statements in accordance with GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. The Company bases its estimates on the information available at the time, its experiences and various other assumptions believed to be reasonable under the circumstances. Adjustments may be made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. Actual results may differ. In the opinion of management, the unaudited Consolidated Condensed Financial Statements for the interim periods presented include all adjustments necessary to present a fair statement of the results for such interim periods. Adverse global macroeconomic conditions, the impact of opioid-related claims and litigation settlements, the influence of certain holidays, seasonality, foreign currency rates, changes in vendor, payor and customer relationships and terms, strategic transactions including acquisitions and dispositions, asset impairments, changes in laws and regulations in the markets in which the Company operates and other factors on the Company’s operations and net earnings for any period may not be comparable to the same period in previous years. Certain amounts in the Consolidated Condensed Financial Statements and accompanying notes may not add due to rounding. Percentages have been calculated using unrounded amounts for all periods presented. Certain prior period data, has been reclassified in the Consolidated Condensed Financial Statements and accompanying notes to conform to the current period presentation. Adoption of new accounting pronouncements Acquired contract assets and contract liabilities in a business combination In October 2021, the FASB issued Accounting Standards Update (“ASU”) 2021-08, Business Combinations (Topic 805) - Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU requires an entity to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606 (Revenue from Contracts with Customers). This ASU is expected to reduce diversity in practice and increase comparability for both the recognition and measurement of acquired revenue contracts with customers at the date of and after a business combination. This ASU is effective for business combinations completed in fiscal years beginning after December 15, 2022 (fiscal 2024). The Company adopted this ASU effective September 1, 2023 and the adoption did not impact the Company's results of operations, cash flows, or financial position. Liabilities — Supplier Finance Programs In September 2022, the FASB issued ASU 2022-04, Liabilities—Supplier Finance Programs (Topic 405-50) - Disclosure of Supplier Finance Program Obligations. This ASU requires that a buyer in a supplier finance program disclose sufficient information about the program to allow a user of financial statements to understand the program’s nature, activity during the period, changes from period to period, and potential magnitude. This ASU is expected to improve financial reporting by requiring new disclosures about the programs, thereby allowing financial statement users to better consider the effect of the programs on an entity’s working capital, liquidity, and cash flows. This ASU is effective for fiscal years beginning after December 15, 2022 (fiscal 2024), except for the amendment on roll forward information which is effective for fiscal years beginning after December 15, 2023 (fiscal 2025). The Company adopted this ASU effective September 1, 2023 and the adoption did not impact the Company's disclosures within these Consolidated Condensed Financial Statements. New accounting pronouncements not yet adopted Leases — Common Control Arrangements In March 2023, the FASB issued ASU 2023-01, Leases (Topic 842) – Common Control Arrangements. The ASU amends the accounting for leasehold improvements in common control arrangements by requiring a lessee in a common control lease arrangement to amortize leasehold improvements that it owns over the improvements’ useful life to the common control group, regardless of the lease term, if the lessee continues to control the use of the underlying asset through a lease. Further, a lessee that no longer controls the use of the underlying asset will derecognize the remaining carrying amount of the improvements through an adjustment to equity, reflecting the transfer of the asset to the lessor under common control. This ASU is effective for fiscal years beginning after December 15, 2023 (fiscal 2025), including interim periods within those fiscal years. Early adoption is permitted in any annual or interim period as of the beginning of the related fiscal year. The Company is evaluating the effect of adopting this new accounting guidance. Segment Reporting - Improvements to Reportable Segment Disclosures In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures. This ASU is expected to improve disclosures related to an entity’s reportable segments and provide additional, more detailed information about a reportable segment’s expenses. This ASU is effective for fiscal years beginning after December 15, 2023 (fiscal 2025) and interim periods within fiscal years beginning after December 15, 2024 (fiscal 2026). The amendments in this ASU must be applied on a retrospective basis to all prior periods presented in the financial statements and early adoption is permitted. The Company is currently evaluating the effect of adopting this new accounting guidance. Improvements to Income Tax Disclosures

Supplemental information

Supplemental information	3 Months Ended
	Nov. 30, 2023
Supplemental Cash Flow Elements [Abstract]
Supplemental information	Supplemental information Accounts receivable Accounts receivable are stated net of allowances for doubtful accounts. Accounts receivable balances primarily consist of trade receivables due from customers, including amounts due from third party payors (e.g., pharmacy benefit managers, insurance companies and governmental agencies). Trade receivables were $4.7 billion and $4.3 billion at November 30, 2023 and August 31, 2023, respectively. Other accounts receivable balances, which consist primarily of receivables from vendors and manufacturers, including receivables from Cencora, were $1.3 billion and $1.1 billion at November 30, 2023 and August 31, 2023, respectively. See Note 16. Related parties for further information. Depreciation and amortization The Company has recorded the following depreciation and amortization expense in the Consolidated Condensed Statements of Earnings (in millions): Three months ended November 30, 2023 2022 Depreciation expense $ 376 $ 336 Intangible assets amortization 240 159 Total depreciation and amortization expense $ 616 $ 495 Accumulated depreciation and amortization on property, plant and equipment was $13.1 billion and $13.0 billion as at November 30, 2023 and August 31, 2023, respectively. Restricted cash The Company is required to maintain cash deposits with certain banks which consist of deposits restricted under contractual agency agreements and cash restricted by law and other obligations. The following represents a reconciliation of Cash and cash equivalents in the Consolidated Condensed Balance Sheets to total Cash, cash equivalents and restricted cash in the Consolidated Condensed Statements of Cash Flows as of November 30, 2023 and August 31, 2023, respectively (in millions): November 30, 2023 August 31, 2023 Cash and cash equivalents $ 784 $ 739 Cash and cash equivalents - assets held for sale (included in other current assets) — 24 Restricted cash - (included in other current and non-current assets) 62 93 Cash, cash equivalents and restricted cash $ 846 $ 856 Redeemable non-controlling interest The following represents a roll forward of the redeemable non-controlling interest in the Consolidated Condensed Balance Sheets (in millions): Three months ended November 30, 2023 2022 Opening balance $ 167 $ 1,042 Net loss attributable to Redeemable non-controlling interests — (22) Redemption price adjustments and other 1 2 452 Reclassifications to Accrued expenses and other liabilities 2 — (1,314) Ending balance $ 169 $ 157 1. Remeasurement of non-controlling interests, probable of redemption but not currently redeemable, to their redemption value, is recorded to Paid in capital in the Consolidated Condensed Balance Sheets. During the three months ended November 30, 2022, Shields and CareCentrix redeemable non-controlling interests were recorded to redemption value as the Company announced the acceleration of its plans for their full ownership. 2. The three months ended November 30, 2022 represents the reclassification of the Shields and CareCentrix redeemable non-controlling interests to Accrued expenses and other liabilities in the Consolidated Condensed Balance Sheets resulting from the Company's full acquisition of Shields and CareCentrix. Earnings per share The dilutive effect of outstanding stock options on earnings per share is calculated using the treasury stock method. Stock options are anti-dilutive and excluded from the earnings per share calculation if the exercise price exceeds the average market price of the common shares. During the three months ended November 30, 2023 and November 30, 2022 there were 16.1 million and 19.3 million weighted outstanding options, respectively, to purchase common shares that were anti-dilutive and excluded from the earnings per share calculation. Due to the anti-dilutive effect resulting from the reported net loss, an incremental 3.7 million and 2.6 million of potentially dilutive securities were omitted from the calculation of weighted-average common shares outstanding for the three months ended November 30, 2023 and November 30, 2022, respectively. Cash dividends declared per common share Cash dividends per common share declared were as follows: Quarter ended 2023 2022 November $ 0.4800 $ 0.4800

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Millions	3 Months Ended
	Nov. 30, 2023	Nov. 30, 2022
Pay vs Performance Disclosure
Net Income (Loss)	$ (67)	$ (3,721)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Nov. 30, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Accounting policies (Policies)

Accounting policies (Policies)	3 Months Ended
	Nov. 30, 2023
Accounting Policies [Abstract]
Basis of presentation	Basis of presentation The Consolidated Condensed Financial Statements of Walgreens Boots Alliance, Inc. and its subsidiaries (“Walgreens Boots Alliance” or the “Company”) included herein have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. The Consolidated Condensed Financial Statements include all subsidiaries in which the Company holds a controlling interest and certain variable interest entities (“VIEs”) for which the Company is the primary beneficiary. The Company uses the equity method of accounting for equity investments in less than majority-owned companies if the investment provides the ability to exercise significant influence. All intercompany transactions have been eliminated. The Consolidated Condensed Financial Statements included herein are unaudited. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited Consolidated Condensed Financial Statements should be read in conjunction with the audited financial statements and the notes thereto included in the Walgreens Boots Alliance Annual Report on Form 10-K for the fiscal year ended August 31, 2023, as amended by Form 10-K/A for the fiscal year ended August 31, 2023 filed on November 22, 2023. The preparation of financial statements in accordance with GAAP requires management to use judgment in the application of accounting policies, including making estimates and assumptions. The Company bases its estimates on the information available at the time, its experiences and various other assumptions believed to be reasonable under the circumstances. Adjustments may be made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. Actual results may differ. In the opinion of management, the unaudited Consolidated Condensed Financial Statements for the interim periods presented include all adjustments necessary to present a fair statement of the results for such interim periods. Adverse global macroeconomic conditions, the impact of opioid-related claims and litigation settlements, the influence of certain holidays, seasonality, foreign currency rates, changes in vendor, payor and customer relationships and terms, strategic transactions including acquisitions and dispositions, asset impairments, changes in laws and regulations in the markets in which the Company operates and other factors on the Company’s operations and net earnings for any period may not be comparable to the same period in previous years. Certain amounts in the Consolidated Condensed Financial Statements and accompanying notes may not add due to rounding. Percentages have been calculated using unrounded amounts for all periods presented. Certain prior period data, has been reclassified in the Consolidated Condensed Financial Statements and accompanying notes to conform to the current period presentation.
Adoption of new accounting pronouncements; New accounting pronouncements not yet adopted	Adoption of new accounting pronouncements Acquired contract assets and contract liabilities in a business combination In October 2021, the FASB issued Accounting Standards Update (“ASU”) 2021-08, Business Combinations (Topic 805) - Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This ASU requires an entity to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606 (Revenue from Contracts with Customers). This ASU is expected to reduce diversity in practice and increase comparability for both the recognition and measurement of acquired revenue contracts with customers at the date of and after a business combination. This ASU is effective for business combinations completed in fiscal years beginning after December 15, 2022 (fiscal 2024). The Company adopted this ASU effective September 1, 2023 and the adoption did not impact the Company's results of operations, cash flows, or financial position. Liabilities — Supplier Finance Programs In September 2022, the FASB issued ASU 2022-04, Liabilities—Supplier Finance Programs (Topic 405-50) - Disclosure of Supplier Finance Program Obligations. This ASU requires that a buyer in a supplier finance program disclose sufficient information about the program to allow a user of financial statements to understand the program’s nature, activity during the period, changes from period to period, and potential magnitude. This ASU is expected to improve financial reporting by requiring new disclosures about the programs, thereby allowing financial statement users to better consider the effect of the programs on an entity’s working capital, liquidity, and cash flows. This ASU is effective for fiscal years beginning after December 15, 2022 (fiscal 2024), except for the amendment on roll forward information which is effective for fiscal years beginning after December 15, 2023 (fiscal 2025). The Company adopted this ASU effective September 1, 2023 and the adoption did not impact the Company's disclosures within these Consolidated Condensed Financial Statements. New accounting pronouncements not yet adopted Leases — Common Control Arrangements In March 2023, the FASB issued ASU 2023-01, Leases (Topic 842) – Common Control Arrangements. The ASU amends the accounting for leasehold improvements in common control arrangements by requiring a lessee in a common control lease arrangement to amortize leasehold improvements that it owns over the improvements’ useful life to the common control group, regardless of the lease term, if the lessee continues to control the use of the underlying asset through a lease. Further, a lessee that no longer controls the use of the underlying asset will derecognize the remaining carrying amount of the improvements through an adjustment to equity, reflecting the transfer of the asset to the lessor under common control. This ASU is effective for fiscal years beginning after December 15, 2023 (fiscal 2025), including interim periods within those fiscal years. Early adoption is permitted in any annual or interim period as of the beginning of the related fiscal year. The Company is evaluating the effect of adopting this new accounting guidance. Segment Reporting - Improvements to Reportable Segment Disclosures In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures. This ASU is expected to improve disclosures related to an entity’s reportable segments and provide additional, more detailed information about a reportable segment’s expenses. This ASU is effective for fiscal years beginning after December 15, 2023 (fiscal 2025) and interim periods within fiscal years beginning after December 15, 2024 (fiscal 2026). The amendments in this ASU must be applied on a retrospective basis to all prior periods presented in the financial statements and early adoption is permitted. The Company is currently evaluating the effect of adopting this new accounting guidance. Improvements to Income Tax Disclosures

Acquisitions and other Invest_2

Acquisitions and other Investments (Tables)	3 Months Ended
	Nov. 30, 2023
Business Combination and Asset Acquisition [Abstract]
Schedule of Identifiable Assets Acquired and Liabilities Assumed	The following table summarizes the consideration for the acquisition and the amounts of identified assets acquired and liabilities assumed at the date of the transaction (in millions): Purchase price allocation Cash consideration 1 $ 4,778 Deferred consideration 100 Summit debt paid at closing 1,963 Fair value of equity consideration 2 1,971 Fair value of non-controlling interests 13 Total $ 8,825 Identifiable assets acquired and liabilities assumed: Cash and cash equivalents $ 69 Accounts receivable, net 382 Property, plant and equipment 607 Intangible assets 3 3,359 Operating lease right-of-use assets 756 Other assets 173 Operating lease obligations (773) Deferred tax liability (737) Other liabilities (470) Total identifiable net assets $ 3,366 Goodwill $ 5,460 1. Cash consideration excludes $87 million of cash paid to fund acquisition-related bonuses to Summit employees which was recognized as compensation expense of the Company. 2. The fair value of the non-controlling interests was calculated based on the implied equity value of VillageMD, allocated to all units on an as-converted basis. 3. Intangibles acquired include provider networks and trade names with fair values of $1.9 billion and $1.5 billion, respectively. Estimated useful lives are 15 years and 11 to 15 years, respectively.
Schedule of Pro Forma Information	The following table represents unaudited supplemental pro forma consolidated sales for the three months ended November 30, 2022, as if the acquisition of Summit had occurred at the beginning of fiscal 2022. The unaudited pro forma information has been prepared for comparative purposes only and is not intended to be indicative of what the Company's results would have been had the acquisition occurred at the beginning of fiscal 2022 or results which may occur in the future. Three months ended November 30, (Unaudited, in millions) 2022 Sales $ 34,099

Exit and disposal activities (T

Exit and disposal activities (Tables)	3 Months Ended
	Nov. 30, 2023
Restructuring and Related Activities [Abstract]
Restructuring and Related Costs	Costs related to exit and disposal activities under the Transformational Cost Management Program for the three months ended November 30, 2023 and 2022, respectively, were as follows (in millions): Three months ended November 30, 2023 U.S. Retail Pharmacy International U.S. Healthcare Corporate and Other Walgreens Boots Alliance, Inc. Lease obligations and other real estate costs $ 36 $ — $ — $ — $ 36 Asset impairments 3 7 — — 10 Employee severance and business transition costs 22 (1) 2 4 27 Information technology transformation and other exit costs 3 — — — 4 Total pre-tax exit and disposal charges $ 64 $ 6 $ 2 $ 4 $ 77 Three months ended November 30, 2022 U.S. Retail Pharmacy International U.S. Healthcare Corporate and Other Walgreens Boots Alliance, Inc. Lease obligations and other real estate costs $ 79 $ — $ — $ — $ 79 Asset impairments 18 — — — 18 Employee severance and business transition costs 11 1 — 4 16 Information technology transformation and other exit costs 11 5 — — 17 Total pre-tax exit and disposal charges $ 119 $ 6 $ — $ 4 $ 130
Change in Restructuring Liabilities	The changes in liabilities and assets related to the exit and disposal activities under Transformational Cost Management Program include the following (in millions): Lease obligations and other real estate costs Asset impairments Employee severance and business transition costs Information technology transformation and other exit costs Total Balance at August 31, 2023 $ 10 $ — $ 70 $ 22 $ 102 Costs 36 10 27 4 77 Payments (21) — (35) (14) (70) Other (10) (10) — — (21) Balance at November 30, 2023 $ 15 $ — $ 62 $ 11 $ 88 O During the three months ended November 30, 2023, VillageMD approved the full or partial exit from 6 markets, including the closure of approximately 70 clinics in fiscal 2024. As a result, long-lived and intangible assets of $124 million were impaired. The impairment charge was recorded in Selling, general and administrative expenses within the Consolidated Condensed Statements of Earnings.

Leases (Tables)

Leases (Tables)	3 Months Ended
	Nov. 30, 2023
Leases [Abstract]
Schedule of Supplemental Balance Sheet Information	Supplemental balance sheet information related to leases was as follows (in millions): Balance sheet supplemental information: November 30, 2023 August 31, 2023 Operating leases: Operating lease right-of-use assets $ 21,708 $ 21,667 Operating lease obligations - current $ 2,350 $ 2,347 Operating lease obligations - non-current 22,132 22,124 Total operating lease obligations $ 24,482 $ 24,472 Finance leases: Right-of-use assets included in: Property, plant and equipment, net $ 663 $ 678 Lease obligations included in: Accrued expenses and other liabilities $ 58 $ 57 Other non-current liabilities 908 919 Total finance lease obligations $ 966 $ 976
Schedule of Supplemental Income Statement and Other Information	Supplemental income statement information related to leases was as follows (in millions): Three months ended November 30, Statement of earnings supplemental information: 2023 2022 Operating lease cost Fixed $ 868 $ 813 Variable 1 214 192 Finance lease cost Amortization $ 19 $ 11 Interest 13 12 Sublease income 2 $ 28 $ 29 Impairment of right-of-use assets 49 67 Gain on sale-leaseback transactions 2 U.S. Retail Pharmacy $ 160 $ 172 International 3 — 17 Total gain on sale-leaseback 2 $ 160 $ 189 1 Includes real estate property taxes, common area maintenance, insurance and rental payments based on sales volume. 2 Recorded in Selling, general and administrative expenses within the Consolidated Condensed Statements of Earnings. 3 Includes gain on sale-leaseback of $17 million related to the optimization of the Germany wholesale business warehouse locations as part of acquisition integration activities in the three months ended November 30, 2022. Other supplemental information was as follows (in millions): Three months ended November 30, Other supplemental information: 2023 2022 Cash paid for amounts included in the measurement of lease obligations Operating cash flows from operating leases $ 924 $ 828 Operating cash flows from finance leases 13 11 Financing cash flows from finance leases 14 10 Total $ 951 $ 849 Right-of-use assets obtained in exchange for new lease obligations Operating leases $ 679 $ 602 Finance leases 5 1 Total $ 685 $ 603 Weighted average lease term and discount rate for real estate leases were as follows: Weighted average lease terms and discount rates: November 30, 2023 August 31, 2023 Weighted average remaining lease term in years Operating leases 9.6 9.6 Finance leases 17.1 17.4 Weighted average discount rate Operating leases 5.43 % 5.35 % Finance leases 5.26 % 5.25 %
Schedule of Aggregate Future Lease Payments Under Operating Leases	The aggregate future lease payments for operating and finance leases as of November 30, 2023 were as follows (in millions): Future lease payments (fiscal years): Finance lease Operating lease 1,2 2024 (Remaining period) $ 84 $ 2,763 2025 106 3,629 2026 102 3,552 2027 100 3,466 2028 91 3,311 2029 85 3,063 Later 880 12,004 Total undiscounted minimum lease payments $ 1,447 $ 31,787 Less: Present value discount 480 7,305 Lease liability $ 966 $ 24,482 1. Total undiscounted minimum lease payments include approximately $3.8 billion of payments related to optional renewal periods that have not been contractually exercised, but are reasonably certain of being exercised. 2. Total undiscounted minimum lease payments exclude sublease rental income of approximately $614 million due to the Company under non-cancelable sublease terms.
Schedule of Aggregate Future Lease Payments Under Finance Leases	The aggregate future lease payments for operating and finance leases as of November 30, 2023 were as follows (in millions): Future lease payments (fiscal years): Finance lease Operating lease 1,2 2024 (Remaining period) $ 84 $ 2,763 2025 106 3,629 2026 102 3,552 2027 100 3,466 2028 91 3,311 2029 85 3,063 Later 880 12,004 Total undiscounted minimum lease payments $ 1,447 $ 31,787 Less: Present value discount 480 7,305 Lease liability $ 966 $ 24,482 1. Total undiscounted minimum lease payments include approximately $3.8 billion of payments related to optional renewal periods that have not been contractually exercised, but are reasonably certain of being exercised. 2. Total undiscounted minimum lease payments exclude sublease rental income of approximately $614 million due to the Company under non-cancelable sublease terms.

Equity method investments (Tabl

Equity method investments (Tables)	3 Months Ended
	Nov. 30, 2023
Equity Method Investments and Joint Ventures [Abstract]
Schedule of Equity Method Investments	Equity method investments were as follows (in millions, except percentages): November 30, 2023 August 31, 2023 Carrying value Ownership percentage Carrying value Ownership percentage Cencora $ 2,430 15% $ 2,534 16% Others 970 8% - 50% 963 8% - 50% Total $ 3,400 $ 3,497 Summarized financial information for the Company’s equity method investment in Cencora is as follows (in millions): Three months ended November 30, Statements of earnings 2023 2022 Sales $ 68,922 $ 61,174 Gross profit 2,211 1,998 Net earnings 351 295 Share of earnings from equity method investments 42 53

Goodwill and other intangible_2

Goodwill and other intangible assets (Tables)	3 Months Ended
	Nov. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The changes in the carrying amount of goodwill by reportable segment are as follows (in millions): Goodwill roll forward: U.S. Retail Pharmacy International U.S. Healthcare Walgreens Boots Alliance, Inc. August 31, 2023 $ 10,947 $ 1,378 $ 15,863 $ 28,187 Adjustments 1 — — 21 21 Cumulative translation adjustments and other — (17) (8) (25) November 30, 2023 $ 10,947 $ 1,361 $ 15,876 $ 28,184 1 Includes measurement period adjustments related to VillageMD's fiscal 2023 acquisitions. See Note 2. Acquisitions and other investments for further information.
Schedule of Finite-Lived Intangible Assets by Major Class	The carrying amount and accumulated amortization of intangible assets consist of the following (in millions): Intangible assets: November 30, 2023 August 31, 2023 Gross amortizable intangible assets Customer relationships and loyalty card holders 1 $ 4,630 $ 4,658 Provider networks 3,148 3,202 Trade names and trademarks 2,296 2,300 Developed technology 469 469 Others 113 137 Total gross amortizable intangible assets $ 10,656 $ 10,767 Accumulated amortization Customer relationships and loyalty card holders 1 $ 1,825 $ 1,784 Provider networks 281 233 Trade names and trademarks 439 401 Developed technology 162 143 Others 52 48 Total accumulated amortization 2,759 2,609 Total amortizable intangible assets, net $ 7,898 $ 8,158 Indefinite-lived intangible assets Trade names and trademarks $ 4,566 $ 4,650 Pharmacy licenses 813 828 Total indefinite-lived intangible assets $ 5,380 $ 5,477 Total intangible assets, net $ 13,278 $ 13,635 1 Includes purchased prescription files.
Schedule of Future Amortization Expense	Estimated future annual amortization expense for the next five fiscal years for intangible assets recorded at November 30, 2023 is as follows (in millions): 2024 (Remaining period) 2025 2026 2027 2028 2029 Estimated annual amortization expense $ 702 $ 901 $ 865 $ 783 $ 706 $ 662

Debt (Tables)

Debt (Tables)	3 Months Ended
	Nov. 30, 2023
Debt Disclosure [Abstract]
Short-Term Borrowings	Debt consists of the following (all amounts are presented in millions of U.S. dollars and debt issuances are denominated in U.S. dollars, unless otherwise noted): November 30, 2023 August 31, 2023 Short-term debt Commercial paper 1 $ 128 $ — Credit facilities 1 November 2021 DDTL due November 2024 290 — $850 million note issuance 1 0.9500% unsecured notes due 2023 — 850 $8 billion note issuance 1 3.800% unsecured notes due 2024 1,156 — Other 2 96 68 Total short-term debt $ 1,670 $ 917 Long-term debt Credit facilities 1 November 2021 DDTL due November 2024 $ — $ 289 December 2022 DDTL due January 2026 999 999 August 2023 DDTL due November 2026 999 — $1.5 billion note issuance 1 3.200% unsecured notes due 2030 498 498 4.100% unsecured notes due 2050 762 793 $6 billion note issuance 1 3.450% unsecured notes due 2026 1,444 1,444 4.650% unsecured notes due 2046 313 318 $8 billion note issuance 1 3.800% unsecured notes due 2024 — 1,156 4.500% unsecured notes due 2034 301 301 4.800% unsecured notes due 2044 805 869 £700 million note issuance 1 3.600% unsecured Pound Sterling notes due 2025 375 381 €750 million note issuance 1 2.125% unsecured Euro notes due 2026 819 814 $4 billion note issuance 3 4.400% unsecured notes due 2042 255 263 Other 2 15 20 Total long-term debt, less current portion $ 7,585 $ 8,145 1 Notes, borrowings under credit facilities and commercial paper are unsecured and unsubordinated debt obligations of the Company and rank equally in right of payment with all other unsecured and unsubordinated indebtedness of the Company from time to time outstanding. 2 Other debt represents a mix of fixed and variable rate debt with various maturities and working capital facilities denominated in various currencies. 3
Long-Term Debt	Debt consists of the following (all amounts are presented in millions of U.S. dollars and debt issuances are denominated in U.S. dollars, unless otherwise noted): November 30, 2023 August 31, 2023 Short-term debt Commercial paper 1 $ 128 $ — Credit facilities 1 November 2021 DDTL due November 2024 290 — $850 million note issuance 1 0.9500% unsecured notes due 2023 — 850 $8 billion note issuance 1 3.800% unsecured notes due 2024 1,156 — Other 2 96 68 Total short-term debt $ 1,670 $ 917 Long-term debt Credit facilities 1 November 2021 DDTL due November 2024 $ — $ 289 December 2022 DDTL due January 2026 999 999 August 2023 DDTL due November 2026 999 — $1.5 billion note issuance 1 3.200% unsecured notes due 2030 498 498 4.100% unsecured notes due 2050 762 793 $6 billion note issuance 1 3.450% unsecured notes due 2026 1,444 1,444 4.650% unsecured notes due 2046 313 318 $8 billion note issuance 1 3.800% unsecured notes due 2024 — 1,156 4.500% unsecured notes due 2034 301 301 4.800% unsecured notes due 2044 805 869 £700 million note issuance 1 3.600% unsecured Pound Sterling notes due 2025 375 381 €750 million note issuance 1 2.125% unsecured Euro notes due 2026 819 814 $4 billion note issuance 3 4.400% unsecured notes due 2042 255 263 Other 2 15 20 Total long-term debt, less current portion $ 7,585 $ 8,145 1 Notes, borrowings under credit facilities and commercial paper are unsecured and unsubordinated debt obligations of the Company and rank equally in right of payment with all other unsecured and unsubordinated indebtedness of the Company from time to time outstanding. 2 Other debt represents a mix of fixed and variable rate debt with various maturities and working capital facilities denominated in various currencies. 3

Financial instruments (Tables)

Financial instruments (Tables)	3 Months Ended
	Nov. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Notional Amounts, Fair Value and Balance Sheet Presentation of Derivative Instruments Outstanding	The notional amounts and fair value of derivative instruments outstanding were as follows (in millions): November 30, 2023 Notional Fair Location in Consolidated Condensed Balance Sheets Derivatives designated as hedges: Foreign currency forwards $ 1 $ — Other current assets Cross currency interest rate swaps 350 12 Other current assets Cross currency interest rate swaps 300 18 Other non-current assets Foreign currency forwards 778 6 Other current liabilities Cross currency interest rate swaps 101 1 Other current liabilities Foreign currency forwards 1 — Other non-current liabilities Derivatives not designated as hedges: Foreign currency forwards $ 352 $ 1 Other current assets Total return swaps 186 8 Other current assets Foreign currency forwards 3,454 19 Other current liabilities Variable prepaid forward contracts 3,726 3,338 Other non-current liabilities August 31, 2023 Notional Fair Location in Consolidated Condensed Balance Sheets Derivatives designated as hedges: Foreign currency forwards $ 31 $ 1 Other current assets Cross currency interest rate swaps 650 28 Other non-current assets Foreign currency forwards 805 2 Other current liabilities Cross currency interest rate swaps 102 2 Other current liabilities Foreign currency forwards 4 — Other non-current liabilities Derivatives not designated as hedges: Foreign currency forwards $ 3,139 $ 6 Other current assets Total return swaps 168 1 Other current assets Foreign currency forwards 817 2 Other current liabilities Total return swaps 26 1 Other current liabilities Variable prepaid forward contracts 3,195 2,548 Other non-current liabilities
Gains and (Losses) due to Changes in Fair Value Recognized in Earnings	The income (expenses) due to changes in fair value of derivative instruments were recognized in the Consolidated Condensed Statements of Earnings as follows (in millions): Three months ended November 30, Location in Consolidated Condensed Statements of Earnings 2023 2022 Total return swap Selling, general and administrative expenses $ (1) $ 4 Foreign currency forwards Other (expense) income, net 1 59 (18) Variable prepaid forward Other (expense) income, net (366) — 1. Excludes remeasurement gains and losses on economically hedged assets and liabilities.
Schedule of Derivative Instruments	The terms of the VPF transactions were as follows (in millions): Transaction date Shares pledged and maximum shares subject to forward sale Prepayment amount Forward settlement date May 11, 2023 4.6 $ 644 Fourth quarter, fiscal 2025 June 15, 2023 2.2 325 Third quarter, fiscal 2025 August 3, 2023 5.3 801 First quarter, fiscal 2026 August 4, 2023 5.3 797 Third quarter, fiscal 2026 November 9, 2023 2.7 424 Fourth quarter, fiscal 2026 20.0 $ 2,991

Fair value measurements (Tables

Fair value measurements (Tables)	3 Months Ended
	Nov. 30, 2023
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis	Assets and liabilities measured at fair value on a recurring basis were as follows (in millions): November 30, 2023 Level 1 Level 2 Level 3 Assets : Money market funds 1 $ 5 $ 5 $ — $ — Cross currency interest rate swaps 2 31 — 31 — Foreign currency forwards 3 1 — 1 — Investments in equity securities 4 18 18 — — Investments in debt securities 5 109 — 109 — Total return swaps 8 — 8 — Liabilities : Variable prepaid forward 6 $ 3,338 $ — $ — $ 3,338 Foreign currency forwards 3 24 — 24 — Cross currency interest rate swaps 2 1 — 1 — August 31, 2023 Level 1 Level 2 Level 3 Assets : Money market funds 1 $ 11 $ 11 $ — $ — Cross currency interest rate swaps 2 28 — 28 — Foreign currency forwards 3 6 — 6 — Investments in equity securities 4 17 17 — — Investments in debt securities 5 15 — 15 — Total return swaps 1 — 1 — Liabilities : Variable prepaid forward 6 $ 2,548 $ — $ — $ 2,548 Foreign currency forwards 3 5 — 5 — Total return swaps 1 — 1 — Cross currency interest rate swaps 2 2 — 2 — 1 Money market funds are valued at the closing price reported by the fund sponsor and classified as Cash and cash equivalents within the Consolidated Condensed Balance Sheets. 2 The fair value of cross currency interest rate swaps is calculated by discounting the estimated future cash flows based on the applicable observable yield curves. See Note 8. Financial instruments, for additional information. 3 The fair value of forward currency contracts is estimated by discounting the difference between the contractual forward price and the current available forward price for the residual maturity of the contract using observable market rates. See Note 8. Financial instruments, for additional information. 4 Fair values of quoted investments are based on current bid prices as of November 30, 2023 and August 31, 2023. 5 Includes investments in Treasury debt securities. 6 The fair value of the derivative was derived from a Black-Scholes valuation. The inputs used in valuing the derivative included observable inputs such as the floor and cap prices of the VPF, dividend yield of Cencora shares, risk free interest rate, and contractual term of the instrument, as well as unobservable inputs such as implied volatility of Cencora shares. The implied volatility ranged from 24.7% - 27.8% for the lower strike and 19.3% - 20.8% for the upper strike as of November 30, 2023, and 23.2% - 24.7% for the lower strike and 18.1% - 19.1% for the upper strike as of August 31, 2023.
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	The roll forward of the fair value of the VPF derivatives associated with the forward sale of shares of Cencora common stock, classified as Level 3, is as follows (in millions): Three months ended November 30, 2023 Opening balance $ (2,548) VPF derivative additions (424) Unrealized losses recorded in Other (expense) income, net (366) Ending balance $ (3,338)

Retirement benefits (Tables)

Retirement benefits (Tables)	3 Months Ended
	Nov. 30, 2023
Retirement Benefits [Abstract]
Components of Net Periodic Benefit Costs (Income)	Components of net periodic pension income for the defined benefit pension plans (in millions): Three months ended November 30, Location in Consolidated Condensed Statements of Earnings 2023 2022 Service costs Selling, general and administrative expenses $ 1 $ 1 Interest costs Other (expense) income, net 70 59 Expected returns on plan assets/other Other (expense) income, net (73) (75) Total net periodic pension income $ (3) $ (15)

Accumulated other comprehensi_2

Accumulated other comprehensive income (loss) (Tables)	3 Months Ended
	Nov. 30, 2023
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Components of Accumulated Other Comprehensive Income (Loss)	The following is a summary of net changes in accumulated other comprehensive income (loss) (“AOCI”) by component and net of tax for the three months ended November 30, 2023 and 2022 (in millions): Pension/ post-retirement obligations Unrealized loss on cash flow hedges and other Net investment hedges Share of OCI of equity method investments Cumulative translation adjustments Total Balance at August 31, 2023 $ (698) $ (6) $ 83 $ (132) $ (2,240) $ (2,993) Other comprehensive income (loss) before reclassification adjustments 77 1 8 (28) (49) 9 Amounts reclassified from AOCI (2) 4 (4) 8 (2) 3 Tax benefit (provision) (19) — (1) 5 — (14) Net change in other comprehensive income (loss) 56 5 3 (15) (51) (2) Balance at November 30, 2023 $ (642) $ (1) $ 86 $ (147) $ (2,291) $ (2,995) Pension/ post-retirement obligations Unrealized loss on cash flow hedges and other Net investment hedges Share of OCI of equity method investments Cumulative translation adjustments Total Balance at August 31, 2022 $ (157) $ (2) $ 213 $ (254) $ (2,605) $ (2,805) Other comprehensive (loss) income before reclassification adjustments — (3) (39) (103) 22 (123) Amounts reclassified from AOCI (7) — — 110 — 103 Tax benefit (provision) 2 1 9 (3) — 9 Net change in other comprehensive (loss) income (5) (2) (29) 4 22 (11) Balance at November 30, 2022 $ (162) $ (4) $ 183 $ (250) $ (2,583) $ (2,815)

Segment reporting (Tables)

Segment reporting (Tables)	3 Months Ended
	Nov. 30, 2023
Segment Reporting [Abstract]
Reconciliation of Operating Income (Loss) from Segments to Consolidated	The following table reflects results of operations of the Company’s reportable segments (in millions): Three months ended November 30, 2023 2022 Sales: U.S. Retail Pharmacy $ 28,944 $ 27,204 International 5,832 5,189 U.S. Healthcare 1,931 989 Walgreens Boots Alliance, Inc. $ 36,707 $ 33,382 Adjusted operating income: U.S. Retail Pharmacy $ 694 $ 1,105 International 142 116 U.S. Healthcare (96) (152) Corporate and Other (53) (56) Walgreens Boots Alliance, Inc. $ 687 $ 1,014 The following table reconciles adjusted operating income to operating loss (in millions): Three months ended November 30, 2023 2022 Adjusted operating income (Non-GAAP measure) $ 687 $ 1,014 Acquisition-related amortization (275) (330) Acquisition-related costs (163) (39) Transformational cost management (109) (138) Certain legal and regulatory accruals and settlements (82) (6,554) Adjustments to equity earnings in Cencora (50) (86) LIFO provision (48) (18) Operating loss (GAAP measure) $ (39) $ (6,151)

Sales (Tables)

Sales (Tables)	3 Months Ended
	Nov. 30, 2023
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The following table summarizes the Company’s sales by segment and by major source (in millions): Three months ended November 30, 2023 2022 U.S. Retail Pharmacy Pharmacy $ 22,384 $ 20,218 Retail 6,560 6,986 Total 28,944 27,204 International Pharmacy 926 867 Retail 1,932 1,650 Wholesale 2,974 2,672 Total 5,832 5,189 U.S. Healthcare 1,931 989 Walgreens Boots Alliance, Inc. $ 36,707 $ 33,382

Related parties (Tables)

Related parties (Tables)	3 Months Ended
	Nov. 30, 2023
Related Party Transactions [Abstract]
Schedule of Related Party Transactions	Related party transactions with Cencora (in millions): Three months ended November 30, 2023 2022 Purchases, net $ 18,311 $ 15,440 November 30, 2023 August 31, 2023 Trade accounts payable, net of receivables $ 8,154 $ 7,814

Supplemental information (Table

Supplemental information (Tables)	3 Months Ended
	Nov. 30, 2023
Supplemental Cash Flow Elements [Abstract]
Schedule of Depreciation and Amortization Expense	The Company has recorded the following depreciation and amortization expense in the Consolidated Condensed Statements of Earnings (in millions): Three months ended November 30, 2023 2022 Depreciation expense $ 376 $ 336 Intangible assets amortization 240 159 Total depreciation and amortization expense $ 616 $ 495
Restrictions on Cash and Cash Equivalents	The following represents a reconciliation of Cash and cash equivalents in the Consolidated Condensed Balance Sheets to total Cash, cash equivalents and restricted cash in the Consolidated Condensed Statements of Cash Flows as of November 30, 2023 and August 31, 2023, respectively (in millions): November 30, 2023 August 31, 2023 Cash and cash equivalents $ 784 $ 739 Cash and cash equivalents - assets held for sale (included in other current assets) — 24 Restricted cash - (included in other current and non-current assets) 62 93 Cash, cash equivalents and restricted cash $ 846 $ 856
Schedule of Redeemable Noncontrolling Interest	The following represents a roll forward of the redeemable non-controlling interest in the Consolidated Condensed Balance Sheets (in millions): Three months ended November 30, 2023 2022 Opening balance $ 167 $ 1,042 Net loss attributable to Redeemable non-controlling interests — (22) Redemption price adjustments and other 1 2 452 Reclassifications to Accrued expenses and other liabilities 2 — (1,314) Ending balance $ 169 $ 157 1. Remeasurement of non-controlling interests, probable of redemption but not currently redeemable, to their redemption value, is recorded to Paid in capital in the Consolidated Condensed Balance Sheets. During the three months ended November 30, 2022, Shields and CareCentrix redeemable non-controlling interests were recorded to redemption value as the Company announced the acceleration of its plans for their full ownership. 2. The three months ended November 30, 2022 represents the reclassification of the Shields and CareCentrix redeemable non-controlling interests to Accrued expenses and other liabilities in the Consolidated Condensed Balance Sheets resulting from the Company's full acquisition of Shields and CareCentrix.
Schedule of Dividends Payable	Cash dividends per common share declared were as follows: Quarter ended 2023 2022 November $ 0.4800 $ 0.4800

Acquisitions and other Invest_3

Acquisitions and other Investments - narrative (Details) - USD ($) $ in Millions			3 Months Ended
	Mar. 03, 2023	Jan. 03, 2023	Nov. 30, 2023	Nov. 30, 2022	Aug. 31, 2023
Business Acquisition [Line Items]
Adjustments			$ 21
Goodwill			28,184		$ 28,187
VillageMD
Business Acquisition [Line Items]
Noncontrolling interest, ownership percentage by parent		53%
Summit Heath-CityMD
Business Acquisition [Line Items]
Cash consideration		$ 7,000
Purchase price		4,850
Fair value of equity consideration		1,971
Deferred consideration		100
Business combination, consideration transferred, employees		87
Summit debt paid at closing		1,900
Adjustments			24
Intangible assets		3,359
Tax deductible goodwill		433
Goodwill		5,460
Summit Heath-CityMD | Partnership Interest
Business Acquisition [Line Items]
Fair value of equity consideration		2,050
Summit Heath-CityMD | Provider networks
Business Acquisition [Line Items]
Intangible assets		$ 1,900
Useful life of capitalized software costs		15 years
Summit Heath-CityMD | Trade Names
Business Acquisition [Line Items]
Intangible assets		$ 1,500
Summit Heath-CityMD | Minimum | Trade Names
Business Acquisition [Line Items]
Useful life of capitalized software costs		11 years
Summit Heath-CityMD | Maximum | Trade Names
Business Acquisition [Line Items]
Useful life of capitalized software costs		15 years
VillageMD
Business Acquisition [Line Items]
Fair value of equity consideration		$ 1,750
Debt instrument, fee amount, credit		220
VillageMD | Line of Credit
Business Acquisition [Line Items]
Face amount		2,250
VillageMD | Line of Credit | Term Loan
Business Acquisition [Line Items]
Face amount		1,750
VillageMD | Line of Credit | Credit facilities
Business Acquisition [Line Items]
Face amount		500
VillageMD | Cigna
Business Acquisition [Line Items]
Fair value of equity consideration		$ 2,500
Starling MSO Holdings, LLC
Business Acquisition [Line Items]
Cash consideration	$ 284
Purchase price	222
Fair value of equity consideration	$ 62
Intangible assets			128
Goodwill			100
Other Acquisitions
Business Acquisition [Line Items]
Cash consideration, net			$ 103	$ 55

Acquisitions and other Invest_4

Acquisitions and other Investments - schedule of purchase price allocation and identifiable assets acquired and liabilities assumed - Summit (Details) - USD ($) $ in Millions	Jan. 03, 2023	Nov. 30, 2023	Aug. 31, 2023
Identifiable assets acquired and liabilities assumed:
Goodwill		$ 28,184	$ 28,187
Summit Heath-CityMD
Purchase price allocation
Cash consideration	$ 4,778
Deferred consideration	100
Summit debt paid at closing	1,963
Fair value of equity consideration	1,971
Fair value of non-controlling interests	13
Total	8,825
Identifiable assets acquired and liabilities assumed:
Cash and cash equivalents	69
Accounts receivable, net	382
Property, plant and equipment	607
Intangible assets	3,359
Operating lease right-of-use assets	756
Other assets	173
Operating lease obligations	(773)
Deferred tax liability	(737)
Other liabilities	(470)
Total identifiable net assets	3,366
Goodwill	$ 5,460

Acquisitions and other Invest_5

Acquisitions and other Investments - Schedule of Pro Forma and Actual Information (Details) $ in Millions	3 Months Ended
	Nov. 30, 2022 USD ($)
Summit Health-CityMD
Business Acquisition [Line Items]
Sales, pro forma	$ 34,099

Exit and disposal activities -

Exit and disposal activities - Narrative (Details) $ in Millions			3 Months Ended	12 Months Ended
	Oct. 12, 2021 USD ($) store	Dec. 20, 2018 USD ($)	Nov. 30, 2023 USD ($) market store clinic	Aug. 31, 2023 USD ($)	Aug. 31, 2022 USD ($)	Nov. 30, 2022 USD ($)	Sep. 01, 2019 USD ($)
Restructuring Cost and Reserve [Line Items]
Cumulative effect adjustment to decrease retained earnings			$ (27,588)	$ (28,322)	$ (29,366)	$ (24,582)
Retained Earnings
Restructuring Cost and Reserve [Line Items]
Cumulative effect adjustment to decrease retained earnings			(32,573)	(33,058)	(37,801)	$ (33,664)
Transformational Cost Management Program
Restructuring Cost and Reserve [Line Items]
Costs incurred			$ 3,200
Number of markets exited | market			6
Number of clinics closed | clinic			70
Transformational Cost Management Program | United Kingdom
Restructuring Cost and Reserve [Line Items]
Number of stores expected to close | store	650
Number of stores closed | store			364
Transformational Cost Management Program | U.S. Retail Pharmacy
Restructuring Cost and Reserve [Line Items]
Number of stores closed | store			563
Transformational Cost Management Program | Retained Earnings | Adoption of New Accounting Standards
Restructuring Cost and Reserve [Line Items]
Cumulative effect adjustment to decrease retained earnings							$ 508
Transformational Cost Management Program
Restructuring Cost and Reserve [Line Items]
Impairment			$ 124
Lease Obligations and Other Real Estate Costs | Transformational Cost Management Program
Restructuring Cost and Reserve [Line Items]
Costs incurred			1,200
Asset Impairments | Transformational Cost Management Program
Restructuring Cost and Reserve [Line Items]
Costs incurred			894
Employee Severance and Business Transition Costs | Transformational Cost Management Program
Restructuring Cost and Reserve [Line Items]
Costs incurred			900
Information Technology Transformation and Other Exit Costs | Transformational Cost Management Program
Restructuring Cost and Reserve [Line Items]
Costs incurred			$ 257
Minimum | Transformational Cost Management Program
Restructuring Cost and Reserve [Line Items]
Expected annual cost savings of restructuring plan	$ 3,300	$ 2,000			3,300
Expected cost				4,100
Minimum | Transformational Cost Management Program | U.S. Retail Pharmacy
Restructuring Cost and Reserve [Line Items]
Number of stores expected to close | store	650
Minimum | Exit and Disposal Costs | Transformational Cost Management Program
Restructuring Cost and Reserve [Line Items]
Expected cost				3,800
Minimum | Transformational Cost Management Program
Restructuring Cost and Reserve [Line Items]
Expected annual cost savings of restructuring plan				3,500
Maximum | Transformational Cost Management Program
Restructuring Cost and Reserve [Line Items]
Expected cost				4,400
Maximum | Transformational Cost Management Program | U.S. Retail Pharmacy
Restructuring Cost and Reserve [Line Items]
Number of stores expected to close | store	700
Maximum | Exit and Disposal Costs | Transformational Cost Management Program
Restructuring Cost and Reserve [Line Items]
Expected cost				4,100
Maximum | Transformational Cost Management Program
Restructuring Cost and Reserve [Line Items]
Expected annual cost savings of restructuring plan				$ 4,500	$ 3,500

Exit and disposal activities _2

Exit and disposal activities - Restructuring Costs (Details) - Transformational Cost Management Program - USD ($) $ in Millions	3 Months Ended
	Nov. 30, 2023	Nov. 30, 2022
Restructuring Cost and Reserve [Line Items]
Total pre-tax exit and disposal charges	$ 77	$ 130
Reportable segments | U.S. Retail Pharmacy
Restructuring Cost and Reserve [Line Items]
Total pre-tax exit and disposal charges	64	119
Reportable segments | International
Restructuring Cost and Reserve [Line Items]
Total pre-tax exit and disposal charges	6	6
Reportable segments | U.S. Healthcare
Restructuring Cost and Reserve [Line Items]
Total pre-tax exit and disposal charges	2	0
Corporate and Other
Restructuring Cost and Reserve [Line Items]
Total pre-tax exit and disposal charges	4	4
Lease obligations and other real estate costs
Restructuring Cost and Reserve [Line Items]
Total pre-tax exit and disposal charges	36	79
Lease obligations and other real estate costs | Reportable segments | U.S. Retail Pharmacy
Restructuring Cost and Reserve [Line Items]
Total pre-tax exit and disposal charges	36	79
Lease obligations and other real estate costs | Reportable segments | International
Restructuring Cost and Reserve [Line Items]
Total pre-tax exit and disposal charges	0	0
Lease obligations and other real estate costs | Reportable segments | U.S. Healthcare
Restructuring Cost and Reserve [Line Items]
Total pre-tax exit and disposal charges	0	0
Lease obligations and other real estate costs | Corporate and Other
Restructuring Cost and Reserve [Line Items]
Total pre-tax exit and disposal charges	0	0
Asset impairments
Restructuring Cost and Reserve [Line Items]
Total pre-tax exit and disposal charges	10	18
Asset impairments | Reportable segments | U.S. Retail Pharmacy
Restructuring Cost and Reserve [Line Items]
Total pre-tax exit and disposal charges	3	18
Asset impairments | Reportable segments | International
Restructuring Cost and Reserve [Line Items]
Total pre-tax exit and disposal charges	7	0
Asset impairments | Reportable segments | U.S. Healthcare
Restructuring Cost and Reserve [Line Items]
Total pre-tax exit and disposal charges	0	0
Asset impairments | Corporate and Other
Restructuring Cost and Reserve [Line Items]
Total pre-tax exit and disposal charges	0	0
Employee severance and business transition costs
Restructuring Cost and Reserve [Line Items]
Total pre-tax exit and disposal charges	27	16
Employee severance and business transition costs | Reportable segments | U.S. Retail Pharmacy
Restructuring Cost and Reserve [Line Items]
Total pre-tax exit and disposal charges	22	11
Employee severance and business transition costs | Reportable segments | International
Restructuring Cost and Reserve [Line Items]
Total pre-tax exit and disposal charges	(1)	1
Employee severance and business transition costs | Reportable segments | U.S. Healthcare
Restructuring Cost and Reserve [Line Items]
Total pre-tax exit and disposal charges	2	0
Employee severance and business transition costs | Corporate and Other
Restructuring Cost and Reserve [Line Items]
Total pre-tax exit and disposal charges	4	4
Information technology transformation and other exit costs
Restructuring Cost and Reserve [Line Items]
Total pre-tax exit and disposal charges	4	17
Information technology transformation and other exit costs | Reportable segments | U.S. Retail Pharmacy
Restructuring Cost and Reserve [Line Items]
Total pre-tax exit and disposal charges	3	11
Information technology transformation and other exit costs | Reportable segments | International
Restructuring Cost and Reserve [Line Items]
Total pre-tax exit and disposal charges	0	5
Information technology transformation and other exit costs | Reportable segments | U.S. Healthcare
Restructuring Cost and Reserve [Line Items]
Total pre-tax exit and disposal charges	0	0
Information technology transformation and other exit costs | Corporate and Other
Restructuring Cost and Reserve [Line Items]
Total pre-tax exit and disposal charges	$ 0	$ 0

Exit and disposal activities _3

Exit and disposal activities - Restructuring Reserve Activity (Details) - Transformational Cost Management Program $ in Millions	3 Months Ended
	Nov. 30, 2023 USD ($)
Restructuring Reserve [Roll Forward]
Beginning balance	$ 102
Costs	77
Payments	(70)
Other	(21)
Ending balance	88
Lease obligations and other real estate costs
Restructuring Reserve [Roll Forward]
Beginning balance	10
Costs	36
Payments	(21)
Other	(10)
Ending balance	15
Asset Impairments
Restructuring Reserve [Roll Forward]
Beginning balance	0
Costs	10
Payments	0
Other	(10)
Ending balance	0
Employee severance and business transition costs
Restructuring Reserve [Roll Forward]
Beginning balance	70
Costs	27
Payments	(35)
Other	0
Ending balance	62
Information technology transformation and other exit costs
Restructuring Reserve [Roll Forward]
Beginning balance	22
Costs	4
Payments	(14)
Other	0
Ending balance	$ 11

Leases - Narrative (Details)

Leases - Narrative (Details) $ in Millions	Nov. 30, 2023 USD ($)
Lessee, Lease, Description [Line Items]
Term of renewal contract	5 years
Undiscounted minimum lease payments, payments associated with options to extend lease terms	$ 3,800
Lessor, operating lease, payments to be received	$ 614
Minimum
Lessee, Lease, Description [Line Items]
Term of lease	10 years
Maximum
Lessee, Lease, Description [Line Items]
Term of lease	25 years

Leases - Supplemental Balance S

Leases - Supplemental Balance Sheet Information (Details) - USD ($) $ in Millions	Nov. 30, 2023	Aug. 31, 2023
Operating Leases:
Operating lease right-of-use assets	$ 21,708	$ 21,667
Operating lease obligations - current	2,350	2,347
Operating lease obligations - non-current	22,132	22,124
Total operating lease obligations	24,482	24,472
Finance leases:
Property, plant and equipment, net	663	678
Lease obligations included in:
Accrued expenses and other liabilities	58	57
Other non-current liabilities	908	919
Total finance lease obligations	$ 966	$ 976
Finance lease, right-of-use asset, statement of financial position, extensible enumeration	Property, plant and equipment, net	Property, plant and equipment, net
Finance lease, liability, current, statement of financial position, extensible enumeration	Accrued expenses and other liabilities	Accrued expenses and other liabilities
Finance lease, liability, noncurrent, statement of financial position, extensible enumeration	Other non-current liabilities	Other non-current liabilities

Leases - Supplemental Income St

Leases - Supplemental Income Statement Information (Details) - USD ($) $ in Millions	3 Months Ended
	Nov. 30, 2023	Nov. 30, 2022
Operating lease cost
Fixed	$ 868	$ 813
Variable	214	192
Finance lease cost
Amortization	19	11
Interest	13	12
Sublease income 2	28	29
Impairment of right-of-use assets	49	67
Gain on sale and leaseback	160	189
U.S. Retail Pharmacy
Finance lease cost
Gain on sale and leaseback	160	172
International
Finance lease cost
Gain on sale and leaseback	$ 0	17
GERMANY | International
Finance lease cost
Gain on sale and leaseback		$ 17

Leases - Other Supplemental Inf

Leases - Other Supplemental Information (Details) - USD ($) $ in Millions	3 Months Ended
	Nov. 30, 2023	Nov. 30, 2022
Cash paid for amounts included in the measurement of lease obligations
Operating cash flows from operating leases	$ 924	$ 828
Operating cash flows from finance leases	13	11
Financing cash flows from finance leases	14	10
Total	951	849
Right-of-use assets obtained in exchange for new lease obligations
Operating leases	679	602
Finance leases	5	1
Total	$ 685	$ 603

Leases - Average Lease Terms An

Leases - Average Lease Terms And Discounts (Details)	Nov. 30, 2023	Aug. 31, 2023
Weighted average remaining lease term in years
Operating leases	9 years 7 months 6 days	9 years 7 months 6 days
Finance leases	17 years 1 month 6 days	17 years 4 months 24 days
Weighted average discount rate
Operating leases	5.43%	5.35%
Finance leases	5.26%	5.25%

Leases - Future Lease Payments

Leases - Future Lease Payments for Operating and Finance Leases (Details) - USD ($) $ in Millions	Nov. 30, 2023	Aug. 31, 2023
Finance lease
2024 (Remaining period)	$ 84
2025	106
2026	102
2027	100
2028	91
2029	85
Later	880
Total undiscounted minimum lease payments	1,447
Less: Present value discount	480
Lease liability	966	$ 976
Operating lease
2024 (Remaining period)	2,763
2025	3,629
2026	3,552
2027	3,466
2028	3,311
2029	3,063
Later	12,004
Total undiscounted minimum lease payments	31,787
Less: Present value discount	7,305
Lease liability	$ 24,482	$ 24,472

Equity method investments - Sch

Equity method investments - Schedule of Equity Method Investments (Details) - USD ($) $ in Millions	Nov. 30, 2023	Aug. 31, 2023
Schedule of Equity Method Investments [Line Items]
Carrying value of equity method investments	$ 3,400	$ 3,497
Cencora
Schedule of Equity Method Investments [Line Items]
Carrying value of equity method investments	$ 2,430	$ 2,534
Ownership percentage	15.30%	15.90%
Others
Schedule of Equity Method Investments [Line Items]
Carrying value of equity method investments	$ 970	$ 963
Others | Minimum
Schedule of Equity Method Investments [Line Items]
Ownership percentage	8%	8%
Others | Maximum
Schedule of Equity Method Investments [Line Items]
Ownership percentage	50%	50%
Total
Schedule of Equity Method Investments [Line Items]
Carrying value of equity method investments	$ 3,400	$ 3,497

Equity method investments - Nar

Equity method investments - Narrative (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended		7 Months Ended	12 Months Ended
	Nov. 30, 2023	Nov. 30, 2022	Nov. 30, 2023	Aug. 31, 2023
Schedule of Equity Method Investments [Line Items]
Gain on sale of equity method investments	$ 139	$ 969
Cencora
Schedule of Equity Method Investments [Line Items]
Outstanding shares owned (in shares)	30.5		30.5	31.8
Ownership percentage	15.30%		15.30%	15.90%
Proceeds from Sale of Equity Method Investments	$ 250	2,000
Gain on sale of equity method investments	139	969
Other comprehensive income (loss) before reclassification adjustments	$ (8)	$ (110)
Period of reporting lag	2 months
Equity investment, exceeded its proportionate share of net assets	$ 2,400		$ 2,400
Cencora | Not Designated as Hedging Instrument
Schedule of Equity Method Investments [Line Items]
Pledged collateral (in shares)			20	17.3
Cencora | Level 1
Schedule of Equity Method Investments [Line Items]
Fair market value of equity investment	$ 6,200		$ 6,200	$ 5,600

Equity method investments - Sum

Equity method investments - Summarized Financial Information of Equity Method Investments (Details) - USD ($) $ in Millions	3 Months Ended
	Nov. 30, 2023	Nov. 30, 2022
Income Statement [Abstract]
Sales	$ 36,707	$ 33,382
Gross profit	6,771	6,953
Net loss	(278)	(3,816)
Share of earnings from equity method investments	42	53
Equity Method Investment
Income Statement [Abstract]
Sales	68,922	61,174
Gross profit	2,211	1,998
Net loss	$ 351	$ 295

Goodwill and other intangible_3

Goodwill and other intangible assets - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Nov. 30, 2023	Nov. 30, 2022	Aug. 31, 2023
Goodwill [Line Items]
Goodwill	$ 28,184		$ 28,187
Indefinite-lived intangible assets	5,380		$ 5,477
Amortization of intangible assets	$ 240	$ 159

Goodwill and other intangible_4

Goodwill and other intangible assets - Schedule of Goodwill (Details) $ in Millions	3 Months Ended
	Nov. 30, 2023 USD ($)
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 28,187
Adjustments	21
Cumulative translation adjustments and other	(25)
Goodwill, ending balance	28,184
Reportable Segments | U.S. Retail Pharmacy
Goodwill [Roll Forward]
Goodwill, beginning balance	10,947
Adjustments	0
Cumulative translation adjustments and other	0
Goodwill, ending balance	10,947
Reportable Segments | International
Goodwill [Roll Forward]
Goodwill, beginning balance	1,378
Adjustments	0
Cumulative translation adjustments and other	(17)
Goodwill, ending balance	1,361
Reportable Segments | U.S. Healthcare
Goodwill [Roll Forward]
Goodwill, beginning balance	15,863
Adjustments	21
Cumulative translation adjustments and other	(8)
Goodwill, ending balance	$ 15,876

Goodwill and other intangible_5

Goodwill and other intangible assets - Schedule of Finite-Lived Intangible Assets by Major Class (Details) - USD ($) $ in Millions	Nov. 30, 2023	Aug. 31, 2023
Finite-Lived Intangible Assets [Line Items]
Gross amortizable intangible assets	$ 10,656	$ 10,767
Accumulated amortization	2,759	2,609
Total amortizable intangible assets, net	7,898	8,158
Indefinite-lived intangible assets	5,380	5,477
Total intangible assets, net	13,278	13,635
Trade names and trademarks
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets	4,566	4,650
Pharmacy licenses
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets	813	828
Customer relationships and loyalty card holders
Finite-Lived Intangible Assets [Line Items]
Gross amortizable intangible assets	4,630	4,658
Accumulated amortization	1,825	1,784
Provider networks
Finite-Lived Intangible Assets [Line Items]
Gross amortizable intangible assets	3,148	3,202
Accumulated amortization	281	233
Trade names and trademarks
Finite-Lived Intangible Assets [Line Items]
Gross amortizable intangible assets	2,296	2,300
Accumulated amortization	439	401
Developed technology
Finite-Lived Intangible Assets [Line Items]
Gross amortizable intangible assets	469	469
Accumulated amortization	162	143
Others
Finite-Lived Intangible Assets [Line Items]
Gross amortizable intangible assets	113	137
Accumulated amortization	$ 52	$ 48

Goodwill and other intangible_6

Goodwill and other intangible assets - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details) $ in Millions	Nov. 30, 2023 USD ($)
Estimated annual intangible assets amortization expense [Abstract]
2024 (Remaining period)	$ 702
2025	901
2026	865
2027	783
2028	706
2029	$ 662

Debt - Short and Long-Term Debt

Debt - Short and Long-Term Debt (Details)	Nov. 30, 2023 USD ($)	Nov. 30, 2023 GBP (£)	Nov. 30, 2023 EUR (€)	Aug. 31, 2023 USD ($)	Nov. 17, 2021 USD ($)
Debt Instrument [Line Items]
Total short-term debt	$ 1,670,000,000			$ 917,000,000
Total long-term debt, less current portion	7,585,000,000			8,145,000,000
Other
Debt Instrument [Line Items]
Total short-term debt	96,000,000			68,000,000
August 2023 DDTL Due January 2026
Debt Instrument [Line Items]
Long-term debt	999,000,000			0
Credit facilities | November 2021 DDTL due November 2024
Debt Instrument [Line Items]
Long-term debt	0			289,000,000
Credit facilities | December 2022 DDTL due January 2026
Debt Instrument [Line Items]
Long-term debt	999,000,000			999,000,000
Unsecured Notes
Debt Instrument [Line Items]
Other	15,000,000			20,000,000
Unsecured Notes | $850 million note issuance
Debt Instrument [Line Items]
Face amount	$ 850,000,000
Unsecured Notes | 0.9500% unsecured notes due 2023
Debt Instrument [Line Items]
Face amount					$ 850,000,000
Stated interest rate	0.95%	0.95%	0.95%		0.95%
Unsecured Notes | Total $8 billion note issuance
Debt Instrument [Line Items]
Face amount	$ 8,000,000,000
Unsecured Notes | 3.800% unsecured notes due 2024
Debt Instrument [Line Items]
Stated interest rate	3.80%	3.80%	3.80%
Long-term debt	$ 0			1,156,000,000
Unsecured Notes | Total $1.5 billion note issuance
Debt Instrument [Line Items]
Face amount	$ 1,500,000,000
Unsecured Notes | 3.200% unsecured notes due 2030
Debt Instrument [Line Items]
Stated interest rate	3.20%	3.20%	3.20%
Long-term debt	$ 498,000,000			498,000,000
Unsecured Notes | 4.100% unsecured notes due 2050
Debt Instrument [Line Items]
Stated interest rate	4.10%	4.10%	4.10%
Long-term debt	$ 762,000,000			793,000,000
Unsecured Notes | Total $6 billion note issuance
Debt Instrument [Line Items]
Face amount	$ 6,000,000,000
Unsecured Notes | 3.450% unsecured notes due 2026
Debt Instrument [Line Items]
Stated interest rate	3.45%	3.45%	3.45%
Long-term debt	$ 1,444,000,000			1,444,000,000
Unsecured Notes | 4.650% unsecured notes due 2046
Debt Instrument [Line Items]
Stated interest rate	4.65%	4.65%	4.65%
Long-term debt	$ 313,000,000			318,000,000
Unsecured Notes | 4.500% unsecured notes due 2034
Debt Instrument [Line Items]
Stated interest rate	4.50%	4.50%	4.50%
Long-term debt	$ 301,000,000			301,000,000
Unsecured Notes | 4.800% unsecured notes due 2044
Debt Instrument [Line Items]
Stated interest rate	4.80%	4.80%	4.80%
Long-term debt	$ 805,000,000			869,000,000
Unsecured Notes | Total £700 million note issuance
Debt Instrument [Line Items]
Face amount | £		£ 700,000,000
Unsecured Notes | 3.600% unsecured Pound Sterling notes due 2025
Debt Instrument [Line Items]
Stated interest rate	3.60%	3.60%	3.60%
Long-term debt	$ 375,000,000			381,000,000
Unsecured Notes | Total €750 million note issuance
Debt Instrument [Line Items]
Face amount | €			€ 750,000,000
Unsecured Notes | 2.125% unsecured Euro notes due 2026
Debt Instrument [Line Items]
Stated interest rate	2.125%	2.125%	2.125%
Long-term debt	$ 819,000,000			814,000,000
Unsecured Notes | Total $4 billion note issuance
Debt Instrument [Line Items]
Face amount	$ 4,000,000,000
Unsecured Notes | 4.400% unsecured notes due 2042
Debt Instrument [Line Items]
Stated interest rate	4.40%	4.40%	4.40%
Long-term debt	$ 255,000,000			263,000,000
Commercial paper
Debt Instrument [Line Items]
Total short-term debt	128,000,000			0
Credit facilities | November 2021 DDTL due November 2024
Debt Instrument [Line Items]
Total short-term debt	290,000,000			0
Unsecured Notes | 0.9500% unsecured notes due 2023
Debt Instrument [Line Items]
Total short-term debt	0			850,000,000
Unsecured Notes | 3.800% unsecured notes due 2024
Debt Instrument [Line Items]
Total short-term debt	$ 1,156,000,000			$ 0

Debt - Narrative (Details)

Debt - Narrative (Details) - USD ($) $ in Millions					3 Months Ended
	Aug. 09, 2023	Jun. 17, 2022	Nov. 17, 2021	Nov. 15, 2021	Nov. 30, 2023	Nov. 30, 2022	Aug. 31, 2023	Dec. 19, 2022
Debt Instrument [Line Items]
Interest paid					$ 177	$ 160
Maximum
Debt Instrument [Line Items]
Debt to total capitalization ratio					0.60
Commercial paper
Debt Instrument [Line Items]
Commercial paper							$ 0
Weighted average interest rate					6.22%
Unsecured Notes | 0.9500% unsecured notes due 2023
Debt Instrument [Line Items]
Face amount			$ 850
Stated interest rate			0.95%		0.95%
Redemption percentage			100%
Credit facilities
Debt Instrument [Line Items]
Remaining borrowing capacity					$ 5,800
Credit facilities | August 2023 Revolving Credit Agreement
Debt Instrument [Line Items]
Face amount	$ 2,250
Debt term	3 years
Borrowing outstanding					0
Credit facilities | August 2023 Revolving Credit Agreement | Maximum | Secured Overnight Financing Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	1.50%
Credit facilities | August 2023 Revolving Credit Agreement | Minimum | Secured Overnight Financing Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	0.75%
Credit facilities | Unsecured Credit Facility, Due August 2023
Debt Instrument [Line Items]
Face amount	$ 1,000
Borrowing outstanding					$ 1,000
Credit facilities | Unsecured Credit Facility, Due August 2023 | Maximum | Secured Overnight Financing Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate					15,000%
Credit facilities | Unsecured Credit Facility, Due August 2023 | Minimum | Secured Overnight Financing Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate					7,500%
Credit facilities | Unsecured Credit Facility, 3 Year Term, Due 2026
Debt Instrument [Line Items]
Face amount								$ 1,000
Borrowing outstanding					$ 1,000
Credit facilities | Unsecured Credit Facility, 3 Year Term, Due 2026 | Maximum | Secured Overnight Financing Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate					15,000%
Credit facilities | Unsecured Credit Facility, 3 Year Term, Due 2026 | Minimum | Secured Overnight Financing Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate					8,750%
Credit facilities | June 17, 2022 Revolving Credit Facility, Five-Year Term
Debt Instrument [Line Items]
Face amount		$ 3,500
Debt term		5 years
Credit facilities | June 17, 2022 Revolving Credit Facility, 18-Month Facility
Debt Instrument [Line Items]
Face amount		$ 1,500
Debt term		18 months
Credit facilities					$ 0
Credit facilities | June 17, 2022 Revolving Credit Facility, 18-Month Facility | Maximum
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate		1.50%
Credit facilities | June 17, 2022 Revolving Credit Facility, 18-Month Facility | Minimum
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate		0.80%
Credit facilities | Delayed Draw Term Loan | Term Loan
Debt Instrument [Line Items]
Face amount				$ 5,000
Credit facilities | Delayed Draw Term Loan Credit Facility, 364-Day Facility | Term Loan
Debt Instrument [Line Items]
Face amount				$ 2,000
Debt term				364 days
Credit facilities | Delayed Draw Term Loan Credit Facility, 364-Day Facility | Term Loan | Secured Overnight Financing Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate				0.75%
Credit facilities | Delayed Draw Term Loan Credit Facility, Two-Year Facility
Debt Instrument [Line Items]
Face amount				$ 2,000
Credit facilities | Delayed Draw Term Loan Credit Facility, Two-Year Facility | Term Loan
Debt Instrument [Line Items]
Debt term				2 years
Amount outstanding					$ 290
Credit facilities | Delayed Draw Term Loan Credit Facility, Two-Year Facility | Term Loan | Secured Overnight Financing Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate				0.88%
Credit facilities | Delayed Draw Term Loan Credit Facility, Three-Year Facility
Debt Instrument [Line Items]
Face amount				$ 1,000
Credit facilities | Delayed Draw Term Loan Credit Facility, Three-Year Facility | Term Loan
Debt Instrument [Line Items]
Debt term				3 years
Credit facilities | Term Loan
Debt Instrument [Line Items]
Face amount				$ 3,000
Credit facilities | Term Loan | June 17, 2022 Revolving Credit Facility, Five-Year Term
Debt Instrument [Line Items]
Debt term		5 years
Credit facilities | Term Loan | June 17, 2022 Revolving Credit Facility, 18-Month Facility
Debt Instrument [Line Items]
Debt term		18 years
Credit facilities | Term Loan | Delayed Draw Term Loan Credit Facility, Three-Year Facility | Secured Overnight Financing Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate				1.05%

Financial instruments - Summary

Financial instruments - Summary of Derivative Instruments (Details) - USD ($) $ in Millions	3 Months Ended
	Nov. 30, 2023	Nov. 30, 2022	Aug. 31, 2023
Foreign currency forwards | Not Designated as Hedging Instrument | Other income, net
Derivatives, Fair Value [Line Items]
Loss on variable prepaid forward contracts	$ 59	$ (18)
Total return swaps | Not Designated as Hedging Instrument | Selling, general and administrative expenses
Derivatives, Fair Value [Line Items]
Loss on variable prepaid forward contracts	(1)	4
Variable Prepaid Forward | Not Designated as Hedging Instrument | Other income, net
Derivatives, Fair Value [Line Items]
Loss on variable prepaid forward contracts	(366)	$ 0
Other current assets | Foreign currency forwards | Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Notional amount, assets	1		$ 31
Fair value, assets	0		1
Other current assets | Foreign currency forwards | Not Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Notional amount, assets	352		3,139
Fair value, assets	1		6
Other current assets | Cross currency interest rate swaps | Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Notional amount, assets	350
Fair value, assets	12
Other current assets | Total return swaps | Not Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Notional amount, assets	186		168
Fair value, assets	8		1
Other non-current assets | Cross currency interest rate swaps | Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Notional amount, assets	300		650
Fair value, assets	18		28
Other current liabilities | Foreign currency forwards | Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Notional amount, liabilities	778		805
Fair value, liabilities	6		2
Other current liabilities | Foreign currency forwards | Not Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Notional amount, liabilities	3,454		817
Fair value, liabilities	19		2
Other current liabilities | Cross currency interest rate swaps | Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Notional amount, liabilities	101		102
Fair value, liabilities	1		2
Other current liabilities | Total return swaps | Not Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Notional amount, liabilities			26
Fair value, liabilities			1
Other non-current liabilities | Foreign currency forwards | Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Notional amount, liabilities	1		4
Fair value, liabilities	0		0
Other non-current liabilities | Variable Prepaid Forward | Not Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Notional amount, liabilities	3,726		3,195
Fair value, liabilities	$ 3,338		$ 2,548

Financial instruments - Summa_2

Financial instruments - Summary of Variable Prepaid Forward Transactions (Details) - USD ($) shares in Millions, $ in Millions						3 Months Ended
	Nov. 09, 2023	Aug. 04, 2023	Aug. 03, 2023	Jun. 15, 2023	May 11, 2023	Nov. 30, 2023	Nov. 30, 2022
Derivatives, Fair Value [Line Items]
Proceeds from variable prepaid forward contracts						$ 424	$ 0
Not Designated as Hedging Instrument
Derivatives, Fair Value [Line Items]
Proceeds from variable prepaid forward contracts						$ 2,991
Not Designated as Hedging Instrument | Variable Prepaid Forward Due Fourth Quarter Fiscal 2025
Derivatives, Fair Value [Line Items]
Pledged collateral (in shares)					4.6
Proceeds from variable prepaid forward contracts					$ 644
Not Designated as Hedging Instrument | Variable Prepaid Forward Due Third Quarter Fiscal 2025
Derivatives, Fair Value [Line Items]
Pledged collateral (in shares)				2.2
Proceeds from variable prepaid forward contracts				$ 325
Not Designated as Hedging Instrument | Variable Prepaid Forward Due First Quarter Fiscal 2026
Derivatives, Fair Value [Line Items]
Pledged collateral (in shares)			5.3
Proceeds from variable prepaid forward contracts			$ 801
Not Designated as Hedging Instrument | Variable Prepaid Forward Due Third Quarter Fiscal 2026
Derivatives, Fair Value [Line Items]
Pledged collateral (in shares)		5.3
Proceeds from variable prepaid forward contracts		$ 797
Not Designated as Hedging Instrument | Variable Prepaid Forward Due Fourth Quarter Fiscal 2026
Derivatives, Fair Value [Line Items]
Pledged collateral (in shares)	2.7
Proceeds from variable prepaid forward contracts	$ 424

Financial instruments - Summa_3

Financial instruments - Summary of Derivative Income and Expenses Due to Fair Value Changes (Details) - Not Designated as Hedging Instrument - USD ($) $ in Millions	3 Months Ended
	Nov. 30, 2023	Nov. 30, 2022
Total return swaps | Selling, general and administrative expenses
Derivatives, Fair Value [Line Items]
Loss on variable prepaid forward contracts	$ (1)	$ 4
Foreign currency forwards | Other income, net
Derivatives, Fair Value [Line Items]
Loss on variable prepaid forward contracts	59	(18)
Variable Prepaid Forward | Other income, net
Derivatives, Fair Value [Line Items]
Loss on variable prepaid forward contracts	$ (366)	$ 0

Fair value measurements- Additi

Fair value measurements- Additional Information (Details) $ in Millions	Nov. 30, 2023 USD ($)	Aug. 31, 2023 USD ($)
Carrying Value
Liabilities [Abstract]
Fair value of long-term notes outstanding	$ 6,700
Estimate of Fair Value Measurement
Liabilities [Abstract]
Carrying value of long-term notes outstanding	5,800
Recurring
Assets [Abstract]
Money market funds	5	$ 11
Investments in equity securities	18	17
Investments in debt securities	109	15
Level 1 | Recurring
Assets [Abstract]
Money market funds	5	11
Investments in equity securities	18	17
Investments in debt securities	0	0
Level 2 | Recurring
Assets [Abstract]
Money market funds	0	0
Investments in equity securities	0	0
Investments in debt securities	$ 109	$ 15
Level 3 | Minimum | Variable Prepaid Forward, Lower Strike | Measurement Input, Price Volatility
Liabilities [Abstract]
Derivative Liability, Measurement Input	0.247	0.232
Level 3 | Minimum | Variable Prepaid Forward, Upper Strike | Measurement Input, Price Volatility
Liabilities [Abstract]
Derivative Liability, Measurement Input	0.193	0.181
Level 3 | Maximum | Variable Prepaid Forward, Lower Strike | Measurement Input, Price Volatility
Liabilities [Abstract]
Derivative Liability, Measurement Input	0.278	0.247
Level 3 | Maximum | Variable Prepaid Forward, Upper Strike | Measurement Input, Price Volatility
Liabilities [Abstract]
Derivative Liability, Measurement Input	0.208	0.191
Level 3 | Recurring
Assets [Abstract]
Money market funds	$ 0	$ 0
Investments in equity securities	0	0
Investments in debt securities	0	0
Foreign currency forwards | Recurring
Assets [Abstract]
Derivative asset	1	6
Liabilities [Abstract]
Derivative liability	24	5
Foreign currency forwards | Level 1 | Recurring
Assets [Abstract]
Derivative asset	0	0
Liabilities [Abstract]
Derivative liability	0	0
Foreign currency forwards | Level 2 | Recurring
Assets [Abstract]
Derivative asset	1	6
Liabilities [Abstract]
Derivative liability	24	5
Foreign currency forwards | Level 3 | Recurring
Assets [Abstract]
Derivative asset	0	0
Liabilities [Abstract]
Derivative liability	0	0
Cross currency interest rate swaps | Recurring
Assets [Abstract]
Derivative asset	31	28
Liabilities [Abstract]
Derivative liability	1	2
Cross currency interest rate swaps | Level 1 | Recurring
Assets [Abstract]
Derivative asset	0	0
Liabilities [Abstract]
Derivative liability	0	0
Cross currency interest rate swaps | Level 2 | Recurring
Assets [Abstract]
Derivative asset	31	28
Liabilities [Abstract]
Derivative liability	1	2
Cross currency interest rate swaps | Level 3 | Recurring
Assets [Abstract]
Derivative asset	0	0
Liabilities [Abstract]
Derivative liability	0	0
Total return swaps | Recurring
Assets [Abstract]
Derivative asset	8	1
Liabilities [Abstract]
Derivative liability		1
Total return swaps | Level 1 | Recurring
Assets [Abstract]
Derivative asset	0	0
Liabilities [Abstract]
Derivative liability		0
Total return swaps | Level 2 | Recurring
Assets [Abstract]
Derivative asset	8	1
Liabilities [Abstract]
Derivative liability		1
Total return swaps | Level 3 | Recurring
Assets [Abstract]
Derivative asset	0	0
Liabilities [Abstract]
Derivative liability		0
Variable Prepaid Forward | Recurring
Liabilities [Abstract]
Derivative liability	3,338	2,548
Variable Prepaid Forward | Level 1 | Recurring
Liabilities [Abstract]
Derivative liability	0	0
Variable Prepaid Forward | Level 2 | Recurring
Liabilities [Abstract]
Derivative liability	0	0
Variable Prepaid Forward | Level 3 | Recurring
Liabilities [Abstract]
Derivative liability	$ 3,338	$ 2,548

Fair value measurements - Fair

Fair value measurements - Fair Value Roll Forward (Details) - Derivative Financial Instruments, Liabilities $ in Millions	3 Months Ended
	Nov. 30, 2023 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Opening balance	$ 2,548
VPF derivative additions	(424)
Unrealized losses recorded in Other (expense) income, net	(366)
Ending balance	$ 3,338

Commitment and contingencies (D

Commitment and contingencies (Details) $ in Millions			1 Months Ended			3 Months Ended
	Nov. 02, 2022 USD ($)	May 05, 2022 USD ($)	Dec. 31, 2023 USD ($)	Aug. 31, 2022 USD ($)	Dec. 31, 2017 case	Nov. 30, 2023 USD ($)	Dec. 31, 2020 case	Aug. 31, 2023 USD ($)	Aug. 23, 2023 USD ($)	Jun. 08, 2023
Loss Contingencies [Line Items]
Accrued litigation obligations						$ 6,366		$ 6,261
Settlement Frameworks | Pending Litigation
Loss Contingencies [Line Items]
Estimated litigation liability						6,500
Accrued litigation obligations	$ 754
Litigation settlement, period	6 years
Settlement Frameworks | Settled Litigation
Loss Contingencies [Line Items]
Estimated litigation liability						6,900
Accrued litigation obligations						6,300
Estimated litigation liability, current						649
Litigation Settlement, Percentage Of Litigating Subdivisions										99.50%
Settling States | Pending Litigation
Loss Contingencies [Line Items]
Estimated litigation liability	$ 4,800
Litigation settlement, period	15 years
Settling Tribes | Pending Litigation
Loss Contingencies [Line Items]
Estimated litigation liability	$ 155
Litigation settlement, period	15 years
Consolidated Cases in State of Florida | Settled Litigation
Loss Contingencies [Line Items]
Litigation settlement, amount awarded to other party		$ 683
Estimated litigation liability								$ 683
Accrued litigation obligations		$ 620
Litigation settlement, period		18 years
Estimated litigation liability, current		$ 63
Ohio Combined Cases | Pending Litigation
Loss Contingencies [Line Items]
Litigation settlement, amount awarded to other party				$ 651
Loss Contingency, New Claims Filed, Number | case					2
Litigation Settlement, Period				15 years
Rite Aid Merger
Loss Contingencies [Line Items]
Loss Contingency, New Claims Filed, Number | case							2
Rite Aid Merger | Pending Litigation
Loss Contingencies [Line Items]
Estimated litigation liability									$ 193
Humana | Settled Litigation
Loss Contingencies [Line Items]
Litigation settlement, amount awarded to other party						642
Accrued litigation obligations						$ 360
Humana | Settled Litigation | Subsequent Event
Loss Contingencies [Line Items]
Payments for legal settlements			$ 150

Income taxes (Details)

Income taxes (Details) - USD ($) $ in Millions	3 Months Ended
	Nov. 30, 2023	Nov. 30, 2022
Income Tax Disclosure [Abstract]
Effective tax rate	(20.70%)	27.50%
Income taxes paid	$ 25	$ 5

Retirement benefits - Narrative

Retirement benefits - Narrative (Details) $ in Millions			3 Months Ended
	Dec. 07, 2023 USD ($)	Nov. 23, 2023 USD ($) member	Nov. 30, 2023 USD ($)
Defined Benefit Plan Disclosure [Line Items]
Accelerated future employer contributions		$ 210
Plan assets, period increase			$ 77
Subsequent Event
Defined Benefit Plan Disclosure [Line Items]
Contributions by employer	$ 375
Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Number of members | member		53,000
Minimum
Defined Benefit Plan Disclosure [Line Items]
Expected future employer contributions		$ 760
Maximum
Defined Benefit Plan Disclosure [Line Items]
Expected future employer contributions		$ 820

Retirement benefits - Schedule

Retirement benefits - Schedule of Net Periodic Pension Income (Details) - USD ($) $ in Millions	3 Months Ended
	Nov. 30, 2023	Nov. 30, 2022
Components of net periodic benefit costs [Abstract]
Service costs	$ 1	$ 1
Interest costs	70	59
Expected returns on plan assets/other	(73)	(75)
Total net periodic pension income	(3)	(15)
U.S. Retail Pharmacy
Components of net periodic benefit costs [Abstract]
Profit sharing provision expense	60	65
Foreign Plan
Components of net periodic benefit costs [Abstract]
Cost recognized in the consolidated condensed statements of earnings	$ 22	$ 20

Accumulated other comprehensi_3

Accumulated other comprehensive income (loss) (Details) - USD ($) $ in Millions	3 Months Ended
	Nov. 30, 2023	Nov. 30, 2022
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	$ 28,322	$ 29,366
Total other comprehensive loss	(5)	(10)
Ending balance	27,588	24,582
Pension/ post-retirement obligations
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(698)	(157)
Other comprehensive income (loss) before reclassification adjustments	77	0
Amounts reclassified from AOCI	(2)	(7)
Tax benefit (provision)	(19)	2
Total other comprehensive loss	56	(5)
Ending balance	(642)	(162)
Unrealized loss on cash flow hedges and other
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(6)	(2)
Other comprehensive income (loss) before reclassification adjustments	1	(3)
Amounts reclassified from AOCI	4	0
Tax benefit (provision)	0	1
Total other comprehensive loss	5	(2)
Ending balance	(1)	(4)
Net investment hedges
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	83	213
Other comprehensive income (loss) before reclassification adjustments	8	(39)
Amounts reclassified from AOCI	(4)	0
Tax benefit (provision)	(1)	9
Total other comprehensive loss	3	(29)
Ending balance	86	183
Share of OCI of equity method investments
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(132)	(254)
Other comprehensive income (loss) before reclassification adjustments	(28)	(103)
Amounts reclassified from AOCI	8	110
Tax benefit (provision)	5	(3)
Total other comprehensive loss	(15)	4
Ending balance	(147)	(250)
Cumulative translation adjustments
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(2,240)	(2,605)
Other comprehensive income (loss) before reclassification adjustments	(49)	22
Amounts reclassified from AOCI	(2)	0
Tax benefit (provision)	0	0
Total other comprehensive loss	(51)	22
Ending balance	(2,291)	(2,583)
Total
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(2,993)	(2,805)
Other comprehensive income (loss) before reclassification adjustments	9	(123)
Amounts reclassified from AOCI	3	103
Tax benefit (provision)	(14)	9
Total other comprehensive loss	(2)	(11)
Ending balance	$ (2,995)	$ (2,815)

Segment reporting (Details)

Segment reporting (Details) $ in Millions	3 Months Ended
	Nov. 30, 2023 USD ($) segment	Nov. 30, 2022 USD ($)
Segment Reporting [Abstract]
Number of reportable segments | segment	3
Segment Reporting Information [Line Items]
Sales	$ 36,707	$ 33,382
Adjusted operating income (Non-GAAP measure)	687	1,014
Acquisition-related amortization	(275)	(330)
Acquisition-related costs	(163)	(39)
Transformational cost management	(109)	(138)
Certain legal and regulatory accruals and settlements	(82)	(6,554)
Adjustments to equity earnings in Cencora	(50)	(86)
LIFO provision	(48)	(18)
Operating loss	(39)	(6,151)
Reportable Segments | U.S. Retail Pharmacy
Segment Reporting Information [Line Items]
Sales	28,944	27,204
Adjusted operating income (Non-GAAP measure)	694	1,105
Reportable Segments | International
Segment Reporting Information [Line Items]
Sales	5,832	5,189
Adjusted operating income (Non-GAAP measure)	142	116
Reportable Segments | U.S. Healthcare
Segment Reporting Information [Line Items]
Sales	1,931	989
Adjusted operating income (Non-GAAP measure)	(96)	(152)
Corporate and Other
Segment Reporting Information [Line Items]
Adjusted operating income (Non-GAAP measure)	$ (53)	$ (56)

Sales (Details)

Sales (Details) - USD ($) $ in Millions	3 Months Ended
	Nov. 30, 2023	Nov. 30, 2022
Disaggregation of Revenue [Line Items]
Sales	$ 36,707	$ 33,382
Reportable Segments | U.S. Retail Pharmacy
Disaggregation of Revenue [Line Items]
Sales	28,944	27,204
Reportable Segments | U.S. Retail Pharmacy | Pharmacy
Disaggregation of Revenue [Line Items]
Sales	22,384	20,218
Reportable Segments | U.S. Retail Pharmacy | Retail
Disaggregation of Revenue [Line Items]
Sales	6,560	6,986
Reportable Segments | International
Disaggregation of Revenue [Line Items]
Sales	5,832	5,189
Reportable Segments | International | Pharmacy
Disaggregation of Revenue [Line Items]
Sales	926	867
Reportable Segments | International | Retail
Disaggregation of Revenue [Line Items]
Sales	1,932	1,650
Reportable Segments | International | Wholesale
Disaggregation of Revenue [Line Items]
Sales	2,974	2,672
Reportable Segments | U.S. Healthcare
Disaggregation of Revenue [Line Items]
Sales	$ 1,931	$ 989

Related parties (Details)

Related parties (Details) - Related Party - Cencora - USD ($) $ in Millions	3 Months Ended
	Nov. 30, 2023	Nov. 30, 2022	Aug. 31, 2023
Related Party Transaction [Line Items]
Purchases, net	$ 18,311	$ 15,440
Trade accounts payable, net of receivables	$ 8,154		$ 7,814

Supplemental information - Narr

Supplemental information - Narrative (Details) - USD ($) shares in Millions, $ in Billions	3 Months Ended
	Nov. 30, 2023	Nov. 30, 2022	Aug. 31, 2023
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accumulated depreciation and amortization on property, plant, and equipment	$ 13.1		$ 13
Antidilutive securities excluded from EPS calculations (in shares)	16.1	19.3
Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements	3.7	2.6
Related Party | Cencora
Accounts, Notes, Loans and Financing Receivable [Line Items]
Receivables	$ 1.3		1.1
Trade Accounts Receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Receivables	$ 4.7		$ 4.3

Supplemental information - Depr

Supplemental information - Depreciation and Amortization Expense (Details) - USD ($) $ in Millions	3 Months Ended
	Nov. 30, 2023	Nov. 30, 2022
Supplemental Cash Flow Elements [Abstract]
Depreciation expense	$ 376	$ 336
Intangible assets amortization	240	159
Total depreciation and amortization expense	$ 616	$ 495

Supplemental information - Summ

Supplemental information - Summary of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Millions	Nov. 30, 2023	Aug. 31, 2023	Nov. 30, 2022	Aug. 31, 2022
Supplemental Cash Flow Elements [Abstract]
Cash and cash equivalents	$ 784	$ 739
Cash and cash equivalents - assets held for sale (included in other current assets)	0	24
Restricted cash - (included in other current and non-current assets)	62	93
Cash, cash equivalents and restricted cash	$ 846	$ 856	$ 4,314	$ 2,558

Supplemental information - Sche

Supplemental information - Schedule of Redeemable Noncontrolling Interest (Details) - USD ($) $ in Millions	3 Months Ended
	Nov. 30, 2023	Nov. 30, 2022
Increase (Decrease) in Temporary Equity [Roll Forward]
Beginning balance	$ 167	$ 1,042
Net loss attributable to Redeemable non-controlling interests	0	(22)
Redemption price adjustments and other	2	452
Reclassifications from redeemable non-controlling interests	0	(1,314)
Ending balance	$ 169	$ 157

Supplemental information - Su_2

Supplemental information - Summary of Dividends per Share (Details) - $ / shares	3 Months Ended
	Nov. 30, 2023	Nov. 30, 2022
Supplemental Cash Flow Elements [Abstract]
Cash dividends declared (in dollars per share)	$ 0.4800	$ 0.4800